GB2435924A - Cellular predictive models for steatosis - Google Patents
Cellular predictive models for steatosis Download PDFInfo
- Publication number
- GB2435924A GB2435924A GB0605358A GB0605358A GB2435924A GB 2435924 A GB2435924 A GB 2435924A GB 0605358 A GB0605358 A GB 0605358A GB 0605358 A GB0605358 A GB 0605358A GB 2435924 A GB2435924 A GB 2435924A
- Authority
- GB
- United Kingdom
- Prior art keywords
- marker
- features
- cells
- steatosis
- phenotypic features
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000007863 steatosis Effects 0.000 title claims abstract description 124
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 124
- 230000001413 cellular effect Effects 0.000 title claims abstract description 51
- 210000004027 cell Anatomy 0.000 claims abstract description 599
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 210
- 238000000034 method Methods 0.000 claims abstract description 206
- 238000010191 image analysis Methods 0.000 claims abstract description 16
- 239000003550 marker Substances 0.000 claims description 264
- 150000001875 compounds Chemical class 0.000 claims description 104
- 238000004590 computer program Methods 0.000 claims description 88
- 150000002632 lipids Chemical class 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 55
- 239000013642 negative control Substances 0.000 claims description 55
- 239000008187 granular material Substances 0.000 claims description 54
- 238000012549 training Methods 0.000 claims description 50
- 238000007637 random forest analysis Methods 0.000 claims description 47
- 238000003066 decision tree Methods 0.000 claims description 46
- 238000004422 calculation algorithm Methods 0.000 claims description 33
- 150000003904 phospholipids Chemical class 0.000 claims description 30
- 230000007935 neutral effect Effects 0.000 claims description 26
- 230000002093 peripheral effect Effects 0.000 claims description 25
- 230000008859 change Effects 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 12
- 102000001479 Member 11 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 claims 16
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 16
- 206010008635 Cholestasis Diseases 0.000 abstract description 41
- 231100000359 cholestasis Toxicity 0.000 abstract description 41
- 230000007870 cholestasis Effects 0.000 abstract description 41
- 231100000304 hepatotoxicity Toxicity 0.000 abstract description 41
- 238000012360 testing method Methods 0.000 abstract description 14
- 230000004071 biological effect Effects 0.000 abstract description 13
- 230000007170 pathology Effects 0.000 description 83
- 238000003556 assay Methods 0.000 description 80
- 210000004940 nucleus Anatomy 0.000 description 76
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 73
- 108010087367 P-glycoprotein 2 Proteins 0.000 description 44
- 206010019851 Hepatotoxicity Diseases 0.000 description 40
- 230000007686 hepatotoxicity Effects 0.000 description 38
- 102000007469 Actins Human genes 0.000 description 32
- 108010085238 Actins Proteins 0.000 description 32
- UXDBPOWEWOXJCE-DIPNUNPCSA-N 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine Chemical compound CCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCCCCCCCCCC UXDBPOWEWOXJCE-DIPNUNPCSA-N 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 210000000941 bile Anatomy 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 230000011218 segmentation Effects 0.000 description 19
- 231100000334 hepatotoxic Toxicity 0.000 description 18
- 230000003082 hepatotoxic effect Effects 0.000 description 18
- 230000001419 dependent effect Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 210000003412 trans-golgi network Anatomy 0.000 description 17
- 230000001988 toxicity Effects 0.000 description 16
- 231100000419 toxicity Toxicity 0.000 description 16
- 230000032258 transport Effects 0.000 description 16
- 230000001587 cholestatic effect Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 11
- 108010078791 Carrier Proteins Proteins 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108010052832 Cytochromes Proteins 0.000 description 8
- 102000018832 Cytochromes Human genes 0.000 description 8
- 230000000877 morphologic effect Effects 0.000 description 8
- 230000008791 toxic response Effects 0.000 description 8
- -1 BSEP Proteins 0.000 description 7
- 230000035508 accumulation Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000012935 Averaging Methods 0.000 description 5
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 5
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 210000003850 cellular structure Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 239000012474 protein marker Substances 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 238000013145 classification model Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000003436 cytoskeletal effect Effects 0.000 description 4
- 210000002288 golgi apparatus Anatomy 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102100030497 Cytochrome c Human genes 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 230000002121 endocytic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 231100000499 nonhepatotoxic Toxicity 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000003702 image correction Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 230000036456 mitotic arrest Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Natural products N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000837849 Homo sapiens Trans-Golgi network integral membrane protein 2 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000025012 Spondias pinnata Species 0.000 description 1
- 235000005658 Spondias pinnata Nutrition 0.000 description 1
- 101000720079 Stichodactyla helianthus DELTA-stichotoxin-She4a Proteins 0.000 description 1
- 102100028621 Trans-Golgi network integral membrane protein 2 Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012062 charged aerosol detection Methods 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
- G06V20/698—Matching; Classification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1488—Methods for deciding
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Quality & Reliability (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Gastroenterology & Hepatology (AREA)
- Multimedia (AREA)
- Signal Processing (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Image Analysis (AREA)
Abstract
Methods for generating models for predicting biological activity of a stimulus on a test population of cells are provided. In particular computer-implemented methods for producing models for classifying a hepatocyte or population of hepatocytes according to whether it exhibits steatosis and also cholestasis or phospholipidosis are presented. Also models are produced for classifying stimuli based on hepatoxicity. The methods may involve receiving a set of phenotypic features of the cells or population of cells that have been exposed to stimuli and treated with one or more markers for particular cellular components by automated image analysis. A subset of the cell populations may be identified to be used in generating a model from data associated with the subset.
Description
<p>S</p>
<p>S * e S * . IS * S ** * : *: :: : 2435924.</p>
<p>555 S**</p>
<p>CELLULAR PREDICTIVE MODELS FOR TOXICITIES</p>
<p>CROSS-REFERENCE TO RELATE[) PATENT APPLiCATIONS</p>
<p>[0001] This application is related to the following patent applications: US Application No. 10/623,486 (Patent Publication No. 20050014216), tiled July 18, 2003 and titled PREDICTING HEPATOTOXICITY IJSINCI CELL BASED ASSAYS; US Application No. 10/719,988 (Patcnt Publication No. 20050014217), filed November 20, 2003, also titled PREDICTING HEPATOTOXICITY USING CELL BASED ASSAYS; US Provisional Application No. 60/757,598, filed January 9, 2006 and titled DOMAIN SEGMENTATION AND ANALYSIS; US Provisional Application No. 60/757,597, filed January 9, 2006 and titled GRANULARITY ANALYSIS IN CELLULAR PHENOTYPES; and US Provisional Application No. 60/758,733, filed January 13, 2006 and titled RANDOM FOREST MODELING OF CELLULAR PHENOTYPES. This application is also related to the fbllowing concurrently filed patent applications: US Provisional Patent Application No. _____________ (Atty Docket No. CYTOP163P2) titled CELL.ULAR PREDICTIVE MODELS FOR TOXIC1T1ES; US Provisional Patent Application No. (Atty Docket No. CYTOPI64P2), also titled CELLULAR PREI)ICTEVE MODELS FOR TOXICITIES; and US Provisional Patent Application No. ______ (Atty Docket No. CYTOP166P2), also titled CELLULAR IRED1CT1VE MODELS FOR TOXICITIES. This application is also related to US Provisional Patent Application No. ___________ (Atty Docket No. CYTOPIO7P), filed March 9, 2006 and titled NORMALIZING CELL ASSAY DATA FOR MODELS. These applications are incorporated herein by reference for all purposes.</p>
<p>[0002] Methods of building and applying models to predict toxicities based on phenotypic characteristics are provided. In certain embodiments, methods of modeling the effects of stimuli on cellular populations usmg appropriate training sets are provided. In certain embodiments, a random forest algorithm is employed to generate decision tree models.</p>
<p>[0003] In drug discovery, valuable infbrmation can be obtained by understanding how a potential therapeutic affects a cell population. Insight may be gained exposing a compound to a stimulus (e.g., a genetic manipulation, exposure to a compound, S..</p>
<p>radiation, or a field, deprivation of required substance, or other perturbation). The ability to quickly determine whether a population of cells exhibits a particular pathology or other classification provides a valuable tool in assessing the mechanism of action or toxicity of an uncharacterized stimulus that has been tested on the population of cells [0004] Models of various forms may be used to classify and/or predict behavior of populations of cells using a large number of previously classified cell populations It would desirable to have additional models that are able to accurately pre(IiCt or classify effects of diverse array of stimuli on the cell populations.</p>
<p>[0005] Some aspects of modeling disclosed herein pertain to generating models tbr classifying stimuli based on hepatotoxicity. Such models may be characterized by the following operations: (a) receiving images of hepatocytes which have been exposed to stimuli and treated with one or more markers for cellular components iii the hepatocytes; (b) extracting two or more phenotypic features from the one or more markers in the images; (c) providing a training set comprising data points including data about the phenotypic features and hepatotoxicity; and (d) from the training set, generating a model classifying stimuli according to whether they are hepatotoxic In some embodiments, the data points comprise (i) the two or more phenotypic features and (ii) an indication of the presence or absence of hepatotoxicity in the stimuli applied to the hepatocytes from which the phenotypic features were obtained. ftc features may he automatically extracted from particular regions of the image, which regions may have been identified by segmentation. In some cases, the features arc derived from whole cell regions occupied by hepatocytes. In other cases, they are derived from particular regions within hepatocytes such as nuclei, peripheral regions of cells, granules within the cells, etc. Certain embodiments, employ features extracted from regions corresponding to granules and/or peripheral regions within the hepatocytes [0006] Other disclosed methods pertain to computer-implemented methods fbr classifying a stimulus according to whether it is hepatotoxic. Such methods may be characterized by the following operations: (a) receiving at least one image of hepatocytes which have been exposed to the stimulus and treated with one or more markers for cellular components in the hepatocytes; (b) automatically extracting two tat * * I I I I * * II * I I It I I * S I I * * S * * S I I * * a * a I tat a'' or more phenotypic features from the one or more markers in the image (c) applying the two or more phenotypic features to a mode! that classifies stimuli according to whether they are hepatotoxic; and (d) receiving a hepatotoxicity classification for the stimulus as an output from the model. As with the method of building model just described, the features used in this method may be extracted from various regions of the image identified by segmentation. In some cases, the features are taken from hepatocytes on a whole cell basis. In other cases, they are derived from particular regions within hepatocytes such as nuclei, peripheral regions of cells, granules within the cells, combinations of these, etc. [0007] In certain embodiments, methods for generating models to classify or predict the hepatotoxic effect of stimuli on cells involve (a) receiving a data set comprising values for dependent variables associated with stimuli; (b) preparing a set of cell populations treated with said stimuli; (c) identifying a subset of the treated cell populations to be used in generating a model fbr classifying hepatotoxicity of stimuli; and (d) generating said model from phenotypic data associated with the subset. The model may be employed to classify stimuli based on hepatotoxic effects they produce in a test population of cells. Methods of classifying hepaloloxicily of a stimulus may involve applying phenotypic data associated with cells treated with the stimulus to a model.</p>
<p>[0008] Still other embodiments described herein pertain to computer-implemented methods of classifying a cell or population of cells by pathology or toxic response.</p>
<p>These methods may be characterized by the following operations: (a) receiving a set of phenotypic features of the cell or population of cells; (h) in a multi-dimensional phenotypic feature space, calculating a measure of difference (e.g., a distance) between at least a first subset of the set of phenotypic features of the cell or population of cells and corresponding phenotypic features of a negative control; (c) determining that the measure of difference calculated in (b) is greater than a threshold value; (d) providing a second subset of the set of phenotypic features from the cell or population of cells as an input to a model for classifying cells based on pathology or toxic response; and (e) receiving a pathology or toxic response classification for the cell or population of cells as an output from the model. Certain embodiments make a determination of whether data from cells or populations of cells have a measure of * * . I I t * * II * I I It I I * I S I I * I I I S I * I ** I I II. *I* difference that is greater than the threshold value. Only the data for these "active" cells or populations is applied to the classification model.</p>
<p>100091 Additionally, certain methods of producing a model for classifying cells according to a pathology or toxic response may be characterized as follows: (a) receiving data points, each comprising (i) a set of phenotypic features of a cell or population of cells and (ii) an indication of whether the pathology or toxic response is present; (b) in a multi-dimensional phenotypic feature space, calculating a measure of difference for each of the data points, between at least a first subset of the set of phenotypic features of the data point and corresponding phenotypic features of a negalive control; (c) identifying those data points having a measure of difference as calculated iii (h) that is greater than a threshold value; and (d) applying an algorithm to the data points identified in (c) to thereby create a model for classifying cells according to the pathology or toxic response based on a second subset of the set of pheiR)typlc tCatures [001 0] Various implementations of the above methods are provided. For example, the first subset of phenotypic features and the second subset of phenotypic features may he (lit fereiit or identical Further, the measures of difference may be calculated as a Fuelideaii distance or a Manhattan distance. In addition, the model for classifying cells based on pathology or toxic response may comprise a decision tree.</p>
<p>In certain embodiments, all phenotypic features may be obtained automatically by image analysis.</p>
<p>[0011] The above methods may be employed to assess a pathology or toxic response associated with hepatocytes. In such cases, the cell or population of cells may comprise a hepatocyte or population of hepatocytes. In some cases, the pathology classification is one or more of cholestasis, steatosis, and phospholipidosis.</p>
<p>[0012] Note that certain embodiments do not rely on difference methods; i.e., they do not employ a measure of difference between phenotypic features of test data and corresponding phenotypic features of a negative control. For example, certain embodiments employ all data from all cell populations (wells) regardless of their "activity" (calculated phenotypic difference from a negative control) to build a S.. * * . a * * * a S ** * S I II S * S * * * * * * a a S I I * S * . S *5* ** classification model. Such models may be used in a manner such that data from any well (regardless of activity level) exposed to a stimulus is submitted for classification.</p>
<p>[0013] At the other extreme, certain approaches build classification models by employing only data from active wells. In such embodiments, model building involves first identifying active wells from among all wells (both positive and negative, for example known cholestatic and non-cholestatic stimuli), and using only active wells to build a model. When using such models, only data from active wells is submitted for classification.</p>
<p>[0014] Other approaches involve intermediate applications of data from active wells.</p>
<p>In one example, models may be built using training sets comprising active wells for a positive class (e.g., cholestatic stimuli) together with data from all wells that for the negative class (e.g., non-cholestatic stimuli) regardless 0! level of activity in the wells of the negative class. When using such models, data from any well (regardless of activity level) exposed to a stimulus may he submitted to a model for classification.</p>
<p>In this approach, there is no need to identify active wells prior to submitting the resulting data to the model for classification.</p>
<p>[0015] In another example, model building employs a training set comprised of three classes: active wells from a positive class (e g., cholestatic compounds), active wells from a negative class (e.g., non-cholestatic compounds), and all wells from a negative control (e.g., wells treated with DMSO). The resulting models may classify stimuli (or cells or populations of cells) according to these three classes. Applying such models to classify cells or stimuli may involve submitting data from any well (regardless of activity level) exposed to a stimulus. As with the immediately prior approach, there is no need to identify active wells prior to submitting the resulting data to the model for classification. A classification from the model indicating that a cell or stimulus is in the same class as the negative control would effectively indicate an inactive stimulus.</p>
<p>[0016] Further aspects of the invention pertain to computer-implemented methods that involve normalization of phenotypic data as part of the process for classifying a stimulus as to toxicity or pathology. Similarly, aspects of the invention pertain to 0I. * * * I * * * * I I. * * S It I * * * I I I * I S S I I * I ** I I methods that involve normalization of phenotypic data in the process of producing models for classifying a stimulus as to toxicity or pathology.</p>
<p>[0017] Certain embodiments involve (a) obtaining one or more phenotypic features from one or more images of cells exposed to a stimulus or stimuli, and (b) normalizing the phenotypic features obtained in (a) using corresponding phenotypic features extracted from one or more images of cells in a negative control. In the context of classifying stimuli, the methods may further involve (c) applying the normalized phenotypic features to a model for classifying stimuli as to toxicity or a pathology associated with cells, and (d) receiving a classification of the stimulus from the model. In the context of producing a model, the methods may involve providing a training set comprising data points, and generating a model from the training set Each data point may include (1) the one or more phenotypic features, as normalized in (b) above, and (ii) an indication of the presence or absence of the toxicity or pathology caused by the stimuli applied to the cells from which the phenotypic features were obtained.</p>
<p>[0018] In some cases, the normalizing operation ((b) above) comprises subtracting mean values of the phenotypic features of the cells of the negative control from values of the phenotypic features of the cells exposed to the stimulus or stimuli, to thereby provide feature difference values. Normalizing may further involve dividing the feature difference values by standard deviations of the correspondmg phenotypic features from the cells of the negative control. In such cases, the corresponding phenotypic features from the negative control may be obtained from multiple negative control wells, which may be provided on one or multiple different plates. In certain embodiments, the mean values of the corresponding phenotypic features from the cells of the negative control are obtained from multiple negative control wells on a single plate. The single plate may include wells for both the cells of the negative control and the cells exposed to the stimulus. As explained elsewhere, the cells of the negative control may be treated with DSMO.</p>
<p>[00191 The features, markers, stimuli, and models may any of those described elsewhere herein. Thus, generally the phenotypic features may comprise at least one of(i) intensities of a marker within cell populations and (ii) morphologies of a marker within cell populations. Further, the phenotypic features may be obtained from one or t S I I I S I * I I ** ::. .. .: :: :: more segmented regions within the cell images. Examples of the segmented regions include granules, nuclei, and peripheral regions within the cells, as well as the whole cells themselves. Further, the model may assume the form of a decision tree or an ensemble of decision trees.</p>
<p>[0020] In certain embodiments, the cell lines to which the model applies are hepatocytes and the pertinent model classifies stimuli as to hepatotoxicity or a pathology associated with hepatocytes (e.g., one or more of cholestasis, steatosis, and phospholipidosis).</p>
<p>[0021] In addition to the above-described methods, the invention pertains to computer program products including machine-readable media on which are stored program instructions for implementing various models. Any of the methods described herein (in whole or part) may he represented, in whole or in part, as program instructions that can be provided on such computer readable media.</p>
<p>[0022] These and other features and advantages of the above embodiments will be described in more detail below, with reference to the associate drawings as appropriate.</p>
<p>[0023] An embodiment or embodiments of the invention will nOW be described in detail, by way of example only, and with reference to the accompanying drawings, in which: [0024] Figure 1 is a flowchart depicting one method of producing a model that can be used to classify or predict activity a population of cells.</p>
<p>[0025] Figure 2 is a simple example of a data set to be used in building a model.</p>
<p>[0026] Figure 3 is a flowchart one method of identifying active wells.</p>
<p>[00271 Figure 4 is a flowchart depicting one method ftr determining whether a particular stimulus and level of stimulus is active.</p>
<p>[0028] Figure 5 is a flowchart depicting one method fbr building a random tree model.</p>
<p>* . .* ** . I II I I * I * I S * : * 4I *.</p>
<p>*,. II. * 10029] Figure 6A is a schematic illustrating a rough example of a partially-grown random tree model.</p>
<p>[0030] Figure âB is a schematic illustrating variable selection for a node of a random tree model.</p>
<p>[003 1] Figure 7 is a flowchart depicting a high level method for evaluating data using a model.</p>
<p>[0032] Figure is a schematic block diagram of an image capture and image processing syslem that can be used in accordance with certain embodiments described herein.</p>
<p>* * .* I I It I * I I I I * I * I I I I * I * I I lit ii.</p>
<p>[0033] Methods for building and applying models to predict the effects of stimuli on cell populations are provided. In certain embodiments, the models predict whether a stimulus will induce particular pathologies or other activities. Such models may classify a stimulus as positive or negative fbr a particular pathology.</p>
<p>[0034] In certain embodiments, the methods for building a model employ a training data set containing independent variables associated with cell populations (e.g., phenotypic characteristics such as intensity and morphological features of markers located within the cells) and at least one dependent variable that classifies the cell populations according to pathology and/or toxicity. Examples of pathology classifications include cholestatis or steatosis. An example of a toxicity classification is hepatotoxicity. In accordance with certain embodiments, the independent variables include cellular phenotype features obtained by automated image analysis.</p>
<p>[0035] In certain embodiments, dependent variables employed in a training data set are obtained from information showing the elkcts of certain stimuli on cells; e.g., the toxicity of various chemical compounds. Such infirmation may be available in the literature, from private sources, by internal research, etc. l'hc information may be in vivo data associated with the stimuli. l'he independent variables employed in the training data set may be obtained by exposing cell populations to the stimuli. In some cases, the stimuli are employed at multiple levels such as multiple concentrations of a chemical compound. In each case, phenotypic features of the treated cells are extracted and used in conjunction with the associated dependent variables to produce the data set.</p>
<p>[0036] In certain embodiments, the training data set is used with an appropriate model generation algorithm such as (i) a random forest technique to produce decision trees, (ii) a regression technique such as partial least squares, or (iii) a technique for generating neural networks. The resulting models may he employed to predict or classify the toxicity of known compounds on a particular cell type.</p>
<p>[0037] As indicated, training data sets may he generated using data from cell populations treated with particular stimuli. The term "cell population" is used interchangeably with "population of cells" A population of cells may include one or more cells. In certain embodiments, a population of cells is the cells in a well oii a * * * * * * S ** * * S St * S I S S 5,5 S* plate. For purposes of discussion, the term "wells" may be used to reference any region occupied by cell populations. In certain embodiments, a population of cells is the cells in a field of view used in obtaining an image of cells in a well or other support medium.</p>
<p>[0038] As indicated, models of this invention may be used to assess the impact of particular stimuli applied to the cell populations. Many types of stimuli arc appropriate and include organic and inorganic materials such as biomolecules, small molecules, etc., pathogens, radiation (including all manner of electromagnetic and particle radiation), tbrces (including mechanical (e.g., gravitational), electrical, magnetic, and nuclear), fields, thermal energy, and the like. Genera! examples of materials that may be used as stimuli include organic and inorganic chemical compounds, biological materials such as nucleic acids, carbohydrates, proteins and peptides, lipids, various infectious agents, mixtures of the foregoing, and the like.</p>
<p>Other general examples of stimuli include temperature, pressure, acoustic energy, electromagnetic radiation, the lack of a particular material (e.g., the lack of oxygen as in ischemia), temporal factors, etc. Various levels of stimuli may be applied to cell populations. For purposes of discussion, reference is primarily made to compounds at concentrations. However, the discussion extends to other stimuli.</p>
<p>[0039] As indicated, in certain embodiments, the models use cellular phenotypic features as "independent variables" or "inputs" when using a model. Numerous cellular phenotypic features, also referred to as descriptors, are known to he useful in predicting a condition or classifying a stimulus. Some of these are described in the following patent documents, each of which is incorporated herein for all purposes: US Patent No. 6,876,76() titled CLASSIFYING CELLS BASED ON INFORMA1l()N CONTAINED EN CELL IMAGES, US Patent Publication No. 2002014452() titled CHARACTERIZING BIOLOGICAL STIMULI BY RESPONSE CURVES, US Patent Publication No. 20020141631 titled IMAGE ANALYSIS OF THE GOLGI COMPLEX, US Patent 6,956,961 titled EXTRACTING SHAPE INFORMATIC)N CONTAINED iN CELL IMAGES, US Patent Publication No. 20050014131 titled METHODS AND APPARATUS FOR INVESTIGATING SIDE EFFECTS, US Patent Publication No. 20050009032 titled METHODS AND APPARATUS FOR CHARACTERISING CELLS AND TREATMENTS, US Patent Publication No. I I I * I * I ** * S I.. *.</p>
<p>20050014216 titled PREDICTING HEPATOTOXICITY USING CELL BASED ASSAYS, and US Patent Publication No. 20050014217, also titled PREDICTING HEPATOTOXICITY USING CELL BASED ASSAYS, US Provisional Patent Application No. 60/509,040, filed July 18, 2003 and titled CHARACTERIZING BIOLOGICAL STIMULI BY RESPONSE CURVES, US Patent Application No. 11/098,020, filed April 1, 2005 and titled METI-lO[) OF CHARACTERIZING CELL SHAPE, US Patent Application No. 11/155,934, filed June 16, 2005 and titled CELLULAR PHENOTYPE, US Patent Application No. 11/192,306, filed July 27, 2005 and titled CELL RESPONSE ASSAY EMPLOYING TIME-LAPSE IMAGING and US Patent Application No. 11/082,241, filed March 15, 2005 and titled ASSAY FOR DISTINGUISHING LIVE AND DEAD CELLS.</p>
<p>[0040] General categories of features include marker intensity and morphological characteristics. These features are typically determined on a per cell basis and then averaged or aggregated over the multiple cells in an image. Typically, though not necessarily, the phenotypic characterizations are derived in whole or in part by automated image analysis.</p>
<p>[0041] Intensity values correlate to marker concentration 1--ugh marker concentrations at particular locations correspond to high signal intensities at pixels associated with the particular locations. Examples of intensity related features include location, population size, and vanous statistical values. Ihe statistical features typically pertain to a concentration or intensity distribution or histogram. Specific examples include mean, standard deviation or variance, skewness, and kurtosis of intensity values within a defined region. The defined region within which such intensity values are evaluated may include, for example, the boundary of a cell, an organelle (e.g., a nucleus), one or more granules, a peripheral region of a cell, etc. Examples of morphological features include various shape and size characteristics such eccentricity, axis ratio for an object fit to an ellipse, perimeter, area, etc. [0042] Some specific examples of feature types suitable for use with this invention include various whole cell and nucleus features where appropriate, cell or object counts, an area, a perimeter, a length, a breadth, a fiber length, a fiber breadth, a shape factor, an elliptical form factor, an inner radius, an outer radius, a mean radius, an equivalent radius, an equivalent sphere volume, an equivalent prolate volume, an 6 6 * * * * 6 *6 * I I I. * * I * S * SI. *** equivalent ohiate volume, an equivalent sphere surface area, a mean intensity, a total intensity, an optical density, a radial dispersion, and a texture difference. These features can he mean or standard deviation values, or frequency statistics from the parameters collected across a population of cells. Further examples employing specific markers will he presented below for models of predicting hepatotoxicity. The phenotypic characterizations may also be derived in whole or in part by techniques other than image analysis.</p>
<p>[0043] Various markers may he considered in developing models for classifying stimuli by effict; e.g., hepatotoxicity and associated pathologies. Among the markers that have been fi)und to provide features useful for modeling hepatotoxicity are markers fir cytoskeletal proteins and structures, canaliculae and proteins therein, endocytic machinery, Golgi components, mitochondria, nuclei, general protein content within a cell, and lipids. In some cases, such markers are employed to show the biological states relevant to hepatotoxicity such as ploidy states.</p>
<p>[0044] Generally, a marker provides a signal that is captured on an image showing the location oF the marker with respect to a cell or particular cellular components. In other words, the location of the signal source (i.e., the location of the marker within the cells) appears in the image. To this end, the marker may be luminescent, radioactive, fluorescent, etc. The labeling agent typically emits a signal at an intensity related to the concentration of the cell component to which the agent is linked. For example, the signal intensity may he directly proportional to the concentration of the underlying cell component [0045] Various slams and compounds may serve as markers. As examples, markers may he designed to hind to particular components already existing a cell (e.g., fluorescently labeled antibodies to particular proteins), be expressed as part of cellular protein (e.g., fusion proteins including yellow fluorescent protein), be transported through a cell (e.g., a labeled tubulin or a labeled phospholipid), etc. Specific examples of such compounds include fluorescently labeled antibodies to the cellular component of interest, fluorescent intercalators, and fluorescent lectins. The antibodies may he uluorescently labeled either directly or indirectly. A few examples of markers relevant to toxicity such as hepatotoxicity will now be briefly described.</p>
<p>* , . * * * S ** * I I II S * I I * I I * a * * I I I I a * . a I I.e S..</p>
<p>[0046] Cytoskeletal markers attach to particular cytoskeletal proteins and/or assemblies thereof such as actin, tubulin, microtuhules, actin filaments, etc. Examples of tubulin markers include fluorescenfly labeled antibodies to tubulin (e.g., DM1-a, YLI-2, and 3A2 antibodies), labeled tuhulin, and the like. Various hepatocyte pathologies including steatosis and cholestasis have an impact on cytoskeletal proteins.</p>
<p>[0047] Markers to canalicular structures and tight Junctions may be used in some models of hepatotoxicity and associated pathologies. Theseinclude markers for various proteins typically found in cana!iculae such as actin, BSEP, and MRP2. As explained elsewhere herein, a change in the canaliculae may indicate cholestasis or other form of hepatocyte pathology such as steatosis.</p>
<p>[0048] Other markers relevant to hepatotoxicity include markers to endocytic structures such as the Golgi apparatus. Examples of markers include antibody markers to the TGN protein p-38 as well as labeled lens culinaris lectin (LC lectin) or antibodies to proteins enriched in the Golgi complex, such as gpl3o, [heta]COP. The TGN is responsible for transporting BSFJ, which has been implicated in hepatotoxicity, particularly chol estasi s [0049] Mitochondrial markers such as markers lr cytochrome C have been found useful in certain models for hepatotoxicity. Some pathologies cause release of cytochrome C from mitochondria followed by migration of the cytochrome C into other regions of the cell. Hence features characterizing the morphology and/or intensity of cytochrome C may be employed iii models of this invention. In certain embodiments, Green Fluorescent Protein ((]Fl') and/or antibodies also can he used to identify the presence of cytochrome C outside the mitochondria. See, e.g., Goldstein et a!. (2000) Nature Cell Biol. 2:156; and Ogawa et al. (2002) Intl. J. Molecular Medicine 10:263. Changes of mitochondrial membrane potential have also been implicated in hepatotoxicity.</p>
<p>[0050] As discussed elsewhere herein, nuclear markers may be employed to segment images to identify cells as well as identify particular features having specific relevance to hepatotoxicity models. DNA markers include fluorescently labeled antibodies to DNA and fluorescent DNA intercalators such DAPI and Hoechst 33341 * * * * * * * 4. I I I I * * * I I I * . I I I I</p>
<p>I</p>
<p>* I * I 1* ItS available from Invitrogen Corporation of Carlsbad, California. The nuclei may also be imaged using histone markers such as GFP-histone2B fusion protein, antibodies to the phosphorylated histones such as (pH3). Note that during mitosis, the histones in the nucleus become phosphorylated. Therefore, mitotic index is measured using a pH3 marker will also give a high reading for the stimuli that induce mitotic arrest.</p>
<p>[0051] Other reagents for segmenting cells include non-specific markers for proteins Examples include succinimidyl esters conjugated to fluorescent dyes such as I'AMRA or Alexa-Fluor dyes. These reagents label primary amine groups of proteins and can be useful in identifying cells within an image. They may also be used to distinguish live and dead cells. The Alexa 647 nm succinimidyl ester reagent (A647SE available from Invitrogen Corporation of Carlsbad, California) may be used to segment individual hepatocytes within an image.</p>
<p>[0052] Lipid markers may bind to neutral or phospholipids. Examples of markers that hind to neutral lipids are Bodipy and Nile Red. In some embodiments described herein, labeled I)IIPE is employed to mark the transport of phospholipids within hepatocytes. lipid transport and accumulation is important in at least steatosis and phospholipidosis.</p>
<p>[0053] Those ol skill in the art will understand that the methods of producing and using models as described herein may be applied to cells and biological materials other than hepatocytcs. Toxicity in other cells such as myocytes, neurons, etc. may be considered in the same manner by generating and using models accordmg to the</p>
<p>description herein</p>
<p>[0054] In certain embodiments, producing models for classifying stimuli on the basis of pathology or other biological effect involves first identifying particular stimuli and/or associated levels (e.g., concentrations) of such stimuli that produce a reasonably strong effect on cells and then using information from only the strongly effecting stimuli/level as a training set for producing a decision tree or any other kind model. Various techniques may be employed to determine whether a level of a particular stimulus has a sufficiently strong effect on cells. In some embodiments, these techniques involve determining phenotypic differences between cells treated with the stimulus and cells in a negative control. One approach involves determining * . S I * * * 6 6. * a I II S S * I I I I * I * * I S I I * I * I S IS. SI* a measure of difference between phenotypic features of the treated and control cells within a multi-dimensional phenotype space. As an example, a Euclidean or Manhattan distance may be calculated in the multidimensional feature space.</p>
<p>Regardless of how one determines whether a particular stimulus or level of stimulus is "active," the training set for building a model may he limited, in some embodiments, to data from active wells or cell populations. Likewise, in certain embodiments, classification of stimuli using models may be limited to those stimuli or levels of stimuli found to be active. Other embodiments, which are described below, employ all stimuli or levels of stimuli regardless of whether they are found to be active.</p>
<p>[0055] Most of the discussion in this application pertains to generation and use of models in the form of decision trees. The invention is not limited in this maimer.</p>
<p>Any form of model may be employed. Examples include, in addition to decision trees, mixture models, linear expressions, non-linear expressions, neural networks, support vector machines, classification algorithms based on distances or differences in inul ti-dimensional phenotypic space, etc. [0056] In some embodiments, the model takes the biiii ol' a decision tree or a group of decision trees. As described below, appropriate decision tree models may be produced using a random forest technique. In certain embodiments, the random forest technique (or other suitable technique) may he employed to produce an ensemble of decision tree models, which are used together to classify cells and the stimuli applied to them. The separate decision trees of the ensemble may be produced using multiple bootstrap samples. In certain embodiments, the bootstrap samples are produced using clustering and/or stratification constraints. As explained below, clustering may be performed based on particular stimuli, with each cluster being a collection of phenotypic data points for various levels of the stimLili (e.g., concentrations of a particular compound applied to a cell population). The bootstrap samples maybe stratified based on the proportions of various pathologies (or other biological effects) in the original data set.</p>
<p>[0057] Figure 1 shows a high-level flow chart illustrating steps in building a model to predict biological activity according to certain embodiments of the present invention using information about cell populations and/or stimuli. In an operation 10!, data including information about one or more pathologies associated with particular I * I I I I * I IS * * a SI I S * a I * S I * * I S S S * S I * 5*1 stimuli is received. The information may be a binary (yes/no) or graded prediction that indicates whether or not the cell population exhibits certain pathologies or other biological effects (e g., whether a particular stimulus applied to the cell population induces a particular pathology or other effect). If the model is to be used to determine whether a cell or population of cells exhibits a particular pathology, then the pathology infhrmation in the data set may serve as a dependent variable. Although the example shown in Figure 1 refers to pathology information, the data set may include infbnnalion about biological conditions in addition to or instead of pathology information (e.g., whether a potential therapeutic stimulus is likely to have a particular side effect, its mechanism of action, etc.).</p>
<p>[0058] A simple example of such data received in operation 101 is presented in Figure 2. l'hc column indicated by reference number 201 identifies different compounds, and the columns indicated by reference numbers 203-209 identify particular pathologies (the dependent variables) that might result from treatment with the eoinpoimds The values in columns 203-207 indicate whether or not the compounds induce the associated pathologies in a cell type or types under consideration In the example presented in Figure 2, three pathologies that may be exhibited by hepatocytes are shown, specifically cholestasis, steatosis and phosphol i pidosi s.</p>
<p>[0059J The example in Figure 2 shows a binary (yes/no) classification for each pathology. In certain embodiments, a predictive score may be used in place of the binary classilication The score may indicate how strongly the toxicity or pathology is exhibited in cells treated with the stimulus (e.g., a percent or degree of activity).</p>
<p>Some data may also he provided with a confidence value indicating a level of confidence that the compound or other stimulus induces the named pathology may be provided in some embodiments. Such information may be employed to "weight" or discard particular data in generating a model. In some cases, the effectiveness of a compound in inducing a pathology may be unknown or not defined; in such cases, the coiiipounds are given the annotation "not defined." [0060J The invention is not limited to models for classifying stimuli on the basis of toxicity or induced pathology. Examples of other dependent variables (classifications) include whether a stimulus induces mitotic arrest, whether it produces sit I * I * I I I I I *I * I I II I * p * * * * I * * I I I S I I I * SI.</p>
<p>"off-target" effects (potential side effects), etc. Examples of non-binary classifications that provide state-based classifications include where in the cell cycle a particular cell currently resides, the mechanism of action of a particular stimulus such as a compound, etc. [0061] In the example shown in Figure 2, reference number 209 indicates whether the compound is considered overall hepatotoxic. Hepatoxicity describes compounds that induce any one or more of the listed pathologies (steatosis, cholestasis, and phospholipidosis) and/or other conditions of hepatocytes such as necrosis, carcinoma, is a PPAR (peroxisome proliferators-activator receptor), etc. [0062] The individual data points in the data set shown in Figure 2 are identified by a stimulus, in this case a compound. l'his information coupled with experimentally derived phenotypic features is then used to build a model to predict biological activity of cells. While the data points depicted in this example are tie(l to particular identified stimuli, this need not be the case. In sonic embodiments, training set data points are comprised of only a dependent variable (e.g., whether a particular condition or effect is exhibited) and independent variables (e g, specific phenotypic features characterizing the cells).</p>
<p>[0063] In some embodiments, the models are built using cell populations treated with compounds at multiple concentrations. Cert ai ii phenotypi c features characteristic of cell populations treated with the compounds (at the multiple concentrations) serve as the inputs or independent variables in the model. A first cell population may be identified as being treated with compound a at concentration C,, a second cell population identified as being treated with compound a at concentration C2, etc. A compound may induce a pathology at all concentrations, only at certain concentrations, or not at all. In certain embodiments, the data received in operation 101 may indicate whether the compound induces a pathology at a particular concentration; in other embodiments, the data may indicate only whether the compound induces a pathology without any indication of the concentrations at which it induces the pathology. In certain embodiments involving the latter case, models may be built using only data from cell populations treated with concentrations of a compound sufficient to induce a significant response in the cell populations. I.</p>
<p>I * 1</p>
<p>I I * I I I I I * * , , . I * I I * I*I II [0064] After the stimulus-condition data is received in operation 101, phenotypic features induced by the particular stimuli may be collected from individual cell populations or wells, each exposed to a unique stimulus (e.g., a particular compound at a particular concentration). See operation 103. As indicated, cell populations may include one or more cells. The stimuli applied to the cell populations or wells prepared in operation 103 are chosen based on the data received in operation I 01.</p>
<p>[0065] One or more wells may he treated with a discrete combination of stimulus and level of stimulus in order to produce a data point used as the stimulus/level data point used in generating the model. In this approach, a data point is comprised of (1) information about a pathology or other biological effect (e.g., whether the associated stimulus is known to induce cholestasis), (2) phenotypic features (and possibly other features) derived from a population of cells treated with the stimulus at a defined level), and optionally (3) the identity of the stimulus and its level of application For example, for the data set shown in Figure 2, wells may be prepared by treating a first well with compound a at concentration c1, treating a second well with compound a at concentration c2, etc. until each compound is represented by 1 0 (litterent Concentrations associated with 10 different wells. In certain embodiments, replicate wells may be prepared (i.e., multiple wells having the same compound at the same concentration, or more generally the same stimulus applied at the same level). Also, as discussed below, in some embodiments multiple plates containing identical or matched wells may be prepared for performing multiple assays. In any case, the data (particularly phenotypic data) taken from these wells is employed to build a predictive model of pathology or other biological effect.</p>
<p>[0066] After the pathology information or other dependent variables associated with cell populations is provided, active" wells (or other cell populations) to he used in building the model are optionally determined in operation 105. Active wells are wells in which the stimulus applied induces some reasonable effect on the cells. Data from wells for which the applied stimulus has little or no effect on cells is not, in certain embodiments, used in building the model. In this approach, only some of the available data points (information derived from wells treated with a particular stimulus) available to generate the model are selected for use in building the predictive model. Those wells (associated with particular stimuli/levels of stimuli) a a</p>
<p>I I a a I</p>
<p> a a a</p>
<p>I I I I</p>
<p>III</p>
<p>deemed or determined to be "active" are used to build the model. Data from other wells ("inactive" wells) are not employed to build the model. In other embodiments, data from all wells, active and inactive, is used to build the model.</p>
<p>[0067] In embodiments where the data received in operation 101 includes concentration-dependent information about the effect of compounds, operation 105 may involve only selecting those concentrations at which compounds are classified as having some effect on the cells (or at which a predictive score or confidence value is above a certain threshold). Concentrations at which compounds are not believed to induce the effect to be modeled are deemed "inactive" and not, in such embodiments, included in the data set employed to build the model. hence data need not be generated from compounds at these concentrations.</p>
<p>[0068] In other embodiments, including embodiments tbr which the data set received in operation 101 is not annotated with concentration information, detecting active wells may involve comparing each well with a reference point (e.g., a negative control) to determine if the compound/concentration applied to the well has a substantial or reasonable effect on the biological activity of the cells.</p>
<p>[0069] Figure 3 shows a flow chart depicting operations of a method of determining active wells according to certain embodiments. In an operation 301, one or more assays are run to determine various phenotypic features of the cell populations in the wells. As indicated, in certain embodiments, features are obtained by analyzing a cell image showing the positions and concentrations of one or more markers associated with particular cellular components (e.g., DNA, Golgi, particular receptors, particular cytoskeletal proteins, etc.). At every combination of compound, dose, and optionally cell line and staining protocol, one or more images can be obtained. As explained, these images are used to extract various parameter values of relevant cellular features.</p>
<p>[0070] Generally a given image of a cell population, as represented by one or more markers, can be analyzed in isolation or combination with other images of the same cell population, as represented by different markers, to obtain any number of image features. As explained above, most features may be characterized as either marker intensity measures or morphological characteristics. Intensity values correlate to marker concentration. High marker concentrations at particular locations correspond I * I I I * I II * I I II I I * I I I I * : * * *, .</p>
<p>III III</p>
<p>to high signal intensities at pixels associated with the particular locations. Examples of intensity related features include location, population size, and various statistical values. The statistical features typically pertain to a concentration or intensity distribution or histogram. Specific examples include mean, standard deviation or variance, skewness, and kurtosis of intensity values within a defined region. The defined region within which such intensity values are evaluated may include, for example, the boundary oU a cell, an organelle (e.g., a nucleus), one or more granules, a peripheral region, etc. Examples of morphological features include various shape and size characteristics such eccentricity, axis ratio for an object fit to an ellipse, perimeter, area, etc. [0071] The phenotypic features associated with a particular stimulus/level of stimulus may be obtained from one well or multiple wells and/or from one or multiple images.</p>
<p>Each well provides data on a discrete population of cells treated with a particular stimulus at a particular level. Multiple assays, each typically using different markers and generating a different collection of features, may be run on multiple plates each containing identical or matched wells (e.g., wells with identical cell lines treated with identical compounds/concentration). Also in some embodiments, replicate wells are used -for example, compound a may he used to treat three cell populations at each concentration. l'hus, for example, if each assay has 10 different concentrations of compound a and 3 replicates, the compound is represented by 30 points in multi-dimensional space (1 0 concentrations times 3 replicates).</p>
<p>[0072] Once the phenotypic features are obtained for each well, all or a subset of features may be compared to control wells to measure the effect of the compound/concentration on the cells in Operation 303. In this manner, "active" wells (data points) may he identified and selected for model building. In the case of experiments based on application of compounds, the control wells may be produced by treating cells in a well with stimulus that is essentially inert (i.e., has little or no biological effect). In certain embodiments, control wells are wells on the same plate treated with DMSO (dimethyl sulfoxide). Of course, various other methods of measuring the effect of the compound/concentrations may be used, including comparing the phenotypic features to a different normalization point.</p>
<p>* . : .. * * * IS * S I St I S * I I I S * S * * S S S S * I S S I.. III [0073] A general method of determining whether a particular stimulus and associated level of that stimulus is sufficiently active for use in building a model involves determining whether cellular phenotypic data associated with that level of stimulus is sufficiently different from phenotypic (lata associated with a negative control (e.g., DMSO treated cells). The phenotypic difference may be measured by various techniques including a distance in phenotype space, a multi-dimensional Kolmogorov-Smirnov or T2 test, an inverse split regression technique, etc. Most of the discussion hereafter assumes a distance in phenotype space is employed to identify active stimuli. Note that the phenotypic features employed to determine such distance need not be the same features employed in models ultimately generated from the data.</p>
<p>[0074] In accordance with certain embodiments, a method fi)r determining whether a particular stimulus and level of stimulus is "active" is depicted in the flow chart of Figure 4. These embodiments assume multiple replicates are prepared for each stimulus/level of stimulus combination. They also assume that the phenotypic data used to calculate phenotypic distance is derived from multiple different assays.</p>
<p>Finally, these embodiments also assume that calculating a separation between phenotypic features from test wells and phenotypic features from DMSO-treated wells (or other negative control wells) involves calculating the Euclidean distance in multi-dimensional space. Note that other measures of distance may he employed such as a Manhattan distance. The multi-dimensional space comprises phenotypic features as dimensions; e.g., mean DNA marker intensity is one dimension, average cell area is a second dimension, etc. [0075] In this method as illustrated in Figure 4, the phcnotypic features for each assay are received in an operation 401 (i.e., the features measured in operation 301). Most or all dimensions (biological features) of each well arc scaled or normalized to a comparable range of values in an operation 403. In one example, this is accomplished by subtracting the mean value of a particular biological feature of the DMSO wells from a particular plate from each of the features of the wells on that plate. (Because the imaging conditions may vary from plate to plate, only the mean of the DMSO values from the particular plate of the well in question are subtracted.) Each feature may be further scaled by dividing the scaled values by one or both of the standard t, lie * 4.</p>
<p>* * II I I * I S I I S 1: . * *** *** I.. *I* deviation of DMSO values for the feature as measured across multiple plates and the standard deviation of all values for the feature as measured across multiple plates.</p>
<p>The scaling of any value of a particular biological feature (dimension) in operation 403 may he given by the following expression: x -ii v -r DMSO on the plate no. ,nal,zed -DMSO acrocv multiple plates where Xis an unsealed value of the feature for a particular well, 1U1)MS() Ofl Iule is the is the mean value of the biological feature across the DMSO values on the plate and UDMS() across nm/tip/c p/ales is the standard deviation of the feature values of the DMSO wells across multiple plates. Multiple plates indicates that the standard deviation is calculated from available data values, and not the oniy the values on the particular plate. The available data values may come from multiple plates in an experiment or from historical data. As indicated, DMSO across multiple plates may he replaced by the standard deviation of the values across all wells of the multiple plates or each feature may he scaled by dividing by both quantities.</p>
<p>[0076] After normalization of the variables, the Euclidean distance or any other measure of difference such as Manhattan LI distance of each well from the DMSO controls is calculated in an operation 405 for each assay. The Euclidean distance is the square root of the sum of the squares of each of the dimensions (features) and the distance (1(X) for each well may be calculated by d(X) (X, -X(control)1)2 where the mean X(control)1 terms are zero if the features have been centered on DMSO (or other control) in operation 403. The median value of the replicates distances is taken in an operation 407 to eliminate outlying data.</p>
<p>* * ** * : : :.</p>
<p>I I I I I</p>
<p>I * S I I S I :.. .:. * [0077] Returning to Figure 3, once the wells have been compared to a normalization point in operation 303, active wells or concentrations are selected in an operation 305.</p>
<p>For example, once the distances for each well are calculated, active wells may be (letermined by selecting those wells that have median distances greater than a threshold distance. It should be noted that in the example shown in Figure 4, a distance is calculated for each of multiple assays. For example, if there are five assays each having a different threshold distance, five different distances are calculated for each compoundlconcentration. Note that each assay may employ the same set of stimulus/level wells but measure features from different markers. A well (e.g., a unique compound/concentration combination) may he designated as active if any of the five distances exceed the threshold. In alternate embodiments, data from all assays may be combined to generate a single distance within a large multi-dimensional space comprised of dimensions taken from all assays. This single distance is compared against a threshold to determine if the stimulus/level is active.</p>
<p>En another approach, a stimulus/level is deemed active only if all or some of the multiple distances (one for each assay) are greater than specified thresholds.</p>
<p>Examples of assays and the features used to calculate distances according to a specific embodiment are shown below.</p>
<p>[0078] The processes shown in Figures 3 and 4 arc examples of a method that may be used to determine active wells. Other methods may be used as well. Further discussions of normalizing dimensions, distance calculations and measuring effects of stimuli may he found in the following applications, which are hereby incorporated by reference for all purposes, U.S. Patent Publication No. 20020155420 titled CHARACTERIZING BIOLOGICAL STIMULI BY RESPONSE CURVES and U.S. Patent Publication No. 20050137806 titled CHARACTERIZING B IOLOGICAL STIMULI BY RESPONSE CURVES. Determining active wells may also be accomplished by other suitable methods including, as mentioned, inverse split regression, multi-dimensional Kolmogorov-Smirnoff, 1.2 methods, random forest and other methods. Manually inspecting each image by eye is another method for detecting active wells. Also in certain embodiments, a concentration may be classified as active if at least a certain percentage (e.g., 25%) of cells are dead. See, e.g., the above-referenced patent application US Patent Application No. 11/082,241, titled ASSAY FOR DISTINGUISHING LIVE AND DEAD CELLS and US Patent * : : : :.</p>
<p>* * I S I I * I * * I I I I :.. ... * * Appliction No (Atty. Docket No. CYTOP155XI) filed February 14, 2006 and titled ASSAY FOR DISTINGUiSHING LIVE AND DEAD CELLS, hereby incorporated by reference in its entirety. Any of these methods may be used alone or in combination with one another (e.g., a well is active if any of the distances meets a threshold or if more than 25% of cells are dead.).</p>
<p>[0079] Referring again to Figure 1, determining active wells in operation 105 results in a training set of compound/concentrations that have a reasonable effect on the cell lines of' interest, each of which is annotated with a binary classification or other predictive value for the pathology (or other dependent variable) of interest. It should he noted that fbr a particular pathology, only the compounds that are annotated as positive or negative may he used in the model. In addition, the training set contains independent variable values (including phenotypic feature values extracted from cell populations treated with the particular compound concentrations) that will be used in building the model. In embodiments where multiple assays are used to obtain feature values, there may be duplicate feature values (e.g., two or more assays may calculatecell area) In these cases, only one of the feature values (e.g., randomly selected from amongst the assays or mean value of the feature taken across multiple assays) may be used in building the model to not give these features undue importance.</p>
<p>[0080] The above discussion assumes that a training set includes employs only data from "active" stimuli for building models of hepatotoxicity. In such embodiments, any stimuli, even those known to he hepatotoxic at certain levels, are not used in the training set ii' they do not elicit a response fiund to be active.</p>
<p>1008 1 The overall process may he summarized as follows. Cells treated with a stimulus under investigation are first analyzed to determine whether they are "active." As indicated, this may involve a determination of whether the treated cells sufficiently different in a phenotypic sense from negative control cells (completely inactive cells).</p>
<p>If the treated cells are not found to be active, they are deemed non-hepatotoxic and their features are not applied to the model. If, however, the treated cells are found to be active, their relevant phenotypic features are applied to the model, which classifies the stimulus on the basis of hepatotoxicity.</p>
<p>* * : ..</p>
<p>* : : : :.</p>
<p>* * . : * . * * * I * I * ii. I..</p>
<p>[0082] In other embodiments, the training set for building the model draws on data from additional sources. In one case, the training set includes data from not only the "active" stimuli but from negative controls and non-hepatotoxic stimuli as well. In such embodiments, all data is used in tile training set except fhr data from inactive hepatotoxic stimuli. As an example, a low concentration of a known hepatotoxic compound produces cells whose phenotypic changes are insufficient to be deemed active. Data from such treatment would not he included in the training set. Models produced using this combination of data from active and inactive stimuli would, in certain embodiments, be used to directly classify any stimulus under investigation, regardless of whether it would be first characterized as active. Hence, an initial step of determining activity is not required with such models. Note that in these embodiments, the concepts of' hepatotoxic and non-hepatotoxic stimuli can be generalized to positive and negative classes of stimuli. Thus, if for example a model is designed to classify stimuli for some specific pathology such as cholestasis, the positive and negative classes might include cholestatic and non-cholestatic compounds. In such example, building tile model would include cholestatic stimuli as one class, and non-cholestatic stimuli as another [0083] In a third example, the training set fbr the hepatotoxicity model includes data from all active stimuli as well as data from a negative control (e.g., hepatocytes treated with DMSO). In this example, the training set will not include data from any inactive stimuli (regardless of whether tile stimuli is known to be hepatotoxic or hot) except for the negative control data, Again, the concept can he generalized from hepatotoxicity models to models for particular pathologies.</p>
<p>[0084] As with other aspects of the invention described herein, it should be understood that the three above examples may be applied to cells and biological materials other than hepatocytes. Toxicity in other cells such as myocytes, neurons, etc. may be considered in the same manner by generating and using models according to the above guidelines. The training sets may he selected using any combination of active and inactive wells from stimuli known to he toxic and non-toxic as described above for hepatocytes.</p>
<p>[0085] Models are built using the training set (lata in operation 107. As indicated, the training set data is optionally limited to active wells -at least for some classes of * V Vt *t I *t * * * 1 IV * let *t **t *ll lit training set data. Decision tree models are one form of model that may be employed in this invention. In certain embodiments, methods provided herein use bootstrapping techniques. Bootstrapping methods involve generating bootstrap samples from an original data set. These bootstrap samples may then be used to generate models of various forms, with decision trees being one example. Bootstrap samples are created by sampling, with replacement, from an original data set to create a new data set (a bootstrap sample) of the same or different size as the original data set. In the methods provided herein, the bootstrap samples are used to generate random forest models.</p>
<p>Bootstrap methods have been shown to improve the robustness of tree models and allow additional analysis of the model (such as variable selection and estimation of the future performance of the model).</p>
<p>[0086] In conventional bootstrap techniques, the bootstrap sample is selected by sampling, with replacement, individual data points from the original data set. In certain embodiments of methods provided herein, however, the data set is clustered prior to generating the bootstrap samples. Clustering involves grouping cell populations by a parameter or characteristic. In certain embodiments, the cell populations are clustered by stimulus, for example by compound. Thus, all cell populations treated with compound a will be in cluster a, all cell populations treated with compound h will he in cluster b, etc. The bootstrap samples are built by randomly sampling clusters, with replacement, to build a sample of the size of the original data set (in terms of number of clusters) or another predetermined sample size. For example, if the original data set contains 100 members, and cacti cluster has members, building each bootstrap sample involves selecting 10 clusters from the clustered data set. Each cluster may be of different size.</p>
<p>[0087] As indicated above, in certain embodiments, the data set is stratified in addition to clustered. The bootstrap samples are then built by randomly sampling clusters, with replacement, within each stratum. In this manner, each bootstrap sample has the same proportion of clusters belonging a particular stratum as the original data set. For example, if there are 400 compounds known to induce cholestasis, 100 compounds that do not induce cholestasis, the data may he divided into strata, the first stratum containing 400 compounds and the second containing I 00.</p>
<p>The data set may then be clustered within each stratum prior to bootstrap sampling.</p>
<p>S * S * * * S If I I t I I * * * S IS. *.* [0088] In addition to pathology, the data set may also be stratified by other parameters, such as chemical properties. Also in certain embodiments, the data set may be sub-stratified. For example, cell populations not exhibiting cholestasis may be further stratified by another pathology or chemical properties, such as exhibiting or not exhibiting steatosis, being part of chemical series or other parameters. Also as indicated above, in cases in which stratification is performed, the bootstrap samples are built by random sampling of clusters within each strata. In this manner, the ratio of the sizes of the strata is maintained. For example, if the data set is stratified by pathology, each bootstrap sample will contain the same proportion of positive (pathology inducing) to negative compounds as the original data set.</p>
<p>[0089] Because the bootstrap samples are built by random sampling of clusters, the likelihood that a particular compound will not he represented in a bootstrap sample (and corresponding random forest model) is greatly increased and equal to l/e=32.7%. For example, if a training set contained 100 wells treated with 10 different compounds, a random sampling of individual wells, with replacement, would almost surely have representatives of each compound. Bootstrap samples generated according the methods of the present, however, are far likelier not to contain any wells treated with a particular compound. This is important because the resulting models are more robust, that is they are able to accurately predict classifications for cells treated with a diverse array of compounds in the future data (or predict classifications for a diverse array of whatever parameter is used to cluster).</p>
<p>[0090] In certain embodiments, the decision tree models are random forest models.</p>
<p>U.S. Patent Provisional Application No. 60/758,733, filed January 13, 2005 titled RANDOM FOREST MODEL[NG OF CELLULAR PHENOTYPES, which is hereby incorporated by reference discusses random forest modeling of cellular phenotypes.</p>
<p>Random forest algorithms use bootstrap samples to generate individual decision trees.</p>
<p>The trees are grown by selecting a random subsample of the independent variables at each node and selecting the variable that produces the best outcome.</p>
<p>[0091] One method of generating a random forest model is shown in Figure 5. The method begins at operation 501 where an original data set S having data about m cell populations is provided. In the example shown in Figure 5, S is the data set resulting from choosing active wells. The data set may also be referred to as a training set and * * . I I I * * * * **</p>
<p>S I I I I S</p>
<p>* . * * * * *</p>
<p>S S I I</p>
<p>*ll *I* includes biological classifications/predictions and phenotypic features (i.e., the dependent and independent variables values) for all cell populations across all compounds, concentrations, replicates, cell lines, etc. For example, each data point in the set may correspond to a population of cells in a well treated with a certain compound at a certain concentration and the independent and dependent variables associated for that well. In operation 503, the data set S is stratified by pathology. For example, in building a model fi)r classifying cells as exhibiting cholestasis or not, the data set may stratified by dividing the data set into populations treated with compounds that are known to induce cholestasis (at any concentration) and those that do not. Thus, if compounds a and b are annotated as cholestasis compounds but compounds c and d are not, the population corresponding to compounds a and b put into the first stratum, and the population corresponding to compounds c and d are put into the second stratum. In operation 505, the data set S is clustered to form a clustered data set S. Clustering the data set involves grouping data points based on a shared parameter. For example, if data points are clustered by compound, all data points corresponding to compound a are put in cluster a, all data points corresponding to compound b are put in cluster b, etc. [0092] From the clustered data set S, multiple bootstrap samples B1 are created in operation 507. Each of these is obtained by sampling, with replacement, from the clustered data set to create a new set with m members. The "with replacement" condition produces variations on the original set S. A bootstrap sample, B1, will sometimes contam replicate samples from S and lack certain samples originally contained in S. Also, because the data set is clustered, selecting a cluster insures all data points in that cluster will he contained in the bootstrap sample B1. It should he noted that when the data set is stratified, each bootstrap sample is obtained by sampling, with replacement, from each stratum such that the ratio of the sizes of the strata (in terms of number of clusters) is the same as in the original data set.</p>
<p>[0093] At operation 509, an unpruned decision tree is built for each bootstrap sample B, in accordance with tile random forest algorithm. At each node of the tree, a subset of independent variables are randomly sampled and tested to determine how well it predicts the dependent variable at the current node. The variable providing the best result is then taken from this subset. In this manner, an unpruned tree is grown fbr : : * , * . : : : * . :.. *:. * * each bootstrap sample B1. The ensemble of all the trees makes up a model that may be applied to data to predict or classify the pathology or activity.</p>
<p>[0094] A simple example of building a random forest model is illustrated in Figures GA and GB. In this example, there are 6 independent variables associated with each well in the bootstrap sample: the intensity of marker 1, the intensity of marker 2, the standard deviation of the intensity of marker 1, the standard deviation of the intensity of marker 1, the standard deviation of the intensity of marker 2, the area of marker I and the area of marker 2. The bootstrap sample contains the values of these independent vanahies for all wells. The bootstrap sample also contains the values of the dependent variable, in this example whether the cells in the well exhibit cholestasis or not. In this example, the size n of the random subset of independent variables is 3. Thus, 3 of the variables are randomly selected for the first node, in Figure 6A, node 601. In this example, iiitensity of marker 1, intensity of marker 2, and standard deviation of marker I are the variables randomly selected for node 601.</p>
<p>Each of these variables is then tested to find the one that best Predicts the known outcomes. Figure 6B shows results of testing each of the randomly selected variables.</p>
<p>Applying decision criteria fbr the first variable, the intensity of marker I (Y if> 10, N if 10), to the bootstrap sample predicts that cells iii wells exhibits cholestasis and do not. Decision criteria for the other selected variables is applied as well. As can he seen in Figure 6B, the prediction made by basing the decision on intensity of marker 1 is closest to the actual results; thus this variable is chosen as the variable on which to base the decision at node 601 in the model. This is indicated in Figure 6A by the line under the selected variable. Other cost functions such as the Gini index may he also used fbr tree building. The tree is then grown, producing two more nodes, nodes 602 and 603. The process of randomly selecting a subset of variables and selecting the best variable on which to base decision is repeated for these nodes. The data is filtered through the previous nodes prior to selecting the best variable; for example selecting the best variable at node 602 is based only on the 45 wells that were predicted "Y" at node 601. The tree is grown, producing nodes 604-607 as shown. Steps 605-607 are repeated to grow the tree. The tree is considered complete or grown when each of the iiodes contains only a single class, i.e. a prediction of 100%.</p>
<p>* I I.. * *1 I I II I S St</p>
<p>I S I S I S</p>
<p>S * * S * S S I :.. *.. * [0095] Figures 6A and 6B illustrate generating a decision tree for a single bootstrap sample. Referring back to Figure 5, operation 509, a decision tree or random tree mode! is grown for each of the bootstrap samples. The ensemble of these trees (i.e., the forest) may he then be used to classify cell populations based on the va!ues of the independent variables associated with them. The example shown in these figures results in a binary (YIN) classification. As indicated above, the random forest algorithm may a!so be used to build regression trees that return numerical values. For example, a number from 0 to I may be used to indicate the likelihood of a cell population exhibiting the activity. Building regression trees employs different cost functions, such as sum of squares of errors, but the process is otherwise similar to building classification trees in that it also includes a single value prediction for each of the nodes.</p>
<p>[0096] Random forest algorithms provide information about the relative importance of the independent variables in predictions. (See, e.g., Leo Breiman, "Random Forests -Random Features," Technical Report 567, University of Calilbrnia, Berkeley, September 1999 and Svetnik et al. "Random Forest for Classification and Regression in QSAR Modeling", which are hereby incorporated by reference). In certain embodiments, after building the model as described above (e.g., using features from the multiple assays), the model may be rebuilt using only features that are determined to have a certain level of importance. If the results are comparable, the model using the smaller number of independent variables is used. This process may he repeated one or more times to find smaller subsets of independent variables that provide results comparable to the initially built model. A similar process may also he used to identify the relative importance of multiple assays.</p>
<p>[0097] Further discussion of the building random forest models may be fbund in above-referenced U.S. Patent Provisional Application No. 601758,733.</p>
<p>[0098] As indicated above, the random forest models may be built using all wells for which there is a known classification or prediction for the pathology or other activity of interest. In an alternate embodiment, the models may be built using DMSO cell populations as well. For example, a random forest model for cholestasis may be built using three types of wells: active wells that are positive for cholestasis, active wells that arc negative for cholestasis, and DMSO wells. The model may then used to * I III *I* *t* * . I. ** * S It I I * I S I I * S * * I I S I</p>
<p>I I I</p>
<p>IfS III classify the test populations into one of three classifications: positive, negative or DMSO-ljke. Alternatively, a model may classify test populations into positive or negative/DMSOlike.</p>
<p>[0099] Figures 5 and 6 describe methods of building random forest models according to certain embodiments. One of skill in the art will understand that various modifications may be made to the described process. Other types of models may also he used including, for example, logistic models for PLD.</p>
<p>[00100] Figures 1-6 describe processes of building classification and regression models for pathologies according to certain embodiments. The models may then be used to classify or predict biological activity of test cell populations (e.g., a population of cell treated with a test compound or other stimulus suspected of inducing a pathology). Figure 7 is a simple flowchart illustrating three high level steps in applying a model to classify a stimulus or its effect on a test population of cells according to certain embodiments. TI-ic process begins at an operation 701 in which active wells are optionally determined as discussed above. In one example, multiple concentrations of a particular compound may he used to treat wells. Only active concentrations or concentrations at which compounds have a reasonable effect on the cell population (e.g., as determined by a comparison to control wells), are applied to any or all of the models. If none of the concentrations are deemed active, then the compound may be deemed inactive. Methods described above fhr determining active concentrations (e.g., determining whether a Euclidean distance is greater than a particular threshold) may be employed thr this purpose.</p>
<p>[00101] In some embodiments, as indicated above, data from any well, regardless of level of activity, is provided to the model. li-i such cases operation 701 is not performed. Rather the independent phenotypic data is provided directly the classification model in use and a stimulus is classified (lirectly.</p>
<p>[00102] Independent variables (e.g., phenotypic features) taken from wells (active wells in some embodiments) are applied to the model in an operation 703.</p>
<p>This operation involves applying the independent variables for each well to the model, which is a collection of random forest trees in the example presented here.</p>
<p>The independent variables are the same as those used to generate the model as * I: ..</p>
<p>* * Is * I I It I I 8 I 8 I * . I * I I I I * , a I It. II* described above, and in certain embodiments, describe phenotypic characteristics of the population. The independent variables are typically obtained by performing the same assays as used to build the model.</p>
<p>[00103] Unlike the data provided in the training set, the dependent variable (e.g., does the cell exhibit cholestasis or hot) is not known for the population of cells -this is what the model deteni-iines. The data is applied to each tree in the ensemble of trees generated as discussed above with regard to Figures 5 and 6. Each tree produces a result or prediction. In certain embodiments, the prediction is binary (yes/no) indicating that the population of cells exhibit or do not exhibit the pathology or classification of interest. In certain embodiments, the result is a numeral indicator of the pathology or classification.</p>
<p>1001 04] As explained above, some methods for building models will produce models that do not require an initial step of filtering stimuli fbr activity. To use such models, one can apply the phenotypic fiatures to the model directly. Such models may provide a negative control (e.g., treatment with a DMSO-like compound or other control) as a one potential output (dependent variable), in addition to activity for the pathology in question and activity hut not for the pathology in question. In evaluating raw data with such models, operation 701 (identifying active wells) may be avoided as the model includes a DMSO-likc classification or prediction.</p>
<p>[00105] In an operation 705, the predictions of all the trees are aggregated. In certain embodiments, the predictions are aggregated by majority vote (e.g., for binary classification) In certain embodiments, the predictions are aggregated by averaging (e.g., for numerical predictions). The aggregate of the predictions of the trees is the result or prediction for the test population or concentration. For example, in certain embodiments, each cell population (e.g., each compound/concentration used to treat the populations) receives a prediction from 0-1 that indicates the likelihood that the cell population exhibits the pathology.</p>
<p>[00106] The well-based prediction or classification information may he analyzed in various ways to give compound-based information (or information on other types of stimulus). In embodiments where replicate wells are used, the median prediction value may be used to eliminate outlier data. In certain embodiments, all Ii I It * I I It a P * a I P P I I * . I I I * I I I it. II.</p>
<p>concentrations that have predictions of at least a threshold prediction value may be identified as positive for the pathology (i.e., inducing the pathology). A minimum concefitration at which an effect is evident may also be identified using the threshold.</p>
<p>In certain embodjmezts the maximum prediction over all concentrations of a compound may he used as an overall prediction of the pathology-inducing ability of the compound</p>
<p>Assay Examples</p>
<p>[00107] As discussed above, assays are used in certain embodiments to generate the phenotypic features employed to build, apply models, or both. In certain embodiments, assays include subjecting cells to one or more stimuli, imaging the cells, and analyzing one or more cell images showing the positions and concentrations of one or more markers located within the cells. A given assay may be characterized by the collection of markers or fCatures employed to define a cellular phenotype. The features obtained are typically chosen to have Some relationship to the biological activity or effect of Interest. The fillowing examples of assays obtain features likely to he related to hepatotoxicity in some cases including one or more hepatotoxic pathologies. Examples of features obtained by the assays are also listed; in one example, the listed features are used to measure separation of phenotypic features obtained in test wells from phenotypic features obtained in on or more control wells, e.g., wells in which the cells are treated with DMSO.</p>
<p>[00108] As indicated above, typical features obtained by the assays may be roughly divided into morphologicil features and intensity-based features.</p>
<p>Morphological features include features that describe, e.g., size, area and elongation (e.g., by axis ratios) and are not specific to a particular marker. Intensity-based features are marker specific and include features that describe total and mean intensities as well as other statistical properties of the intensity of a marker such skewness and kurtosis, which may indicate if the material labeled by the marker (e.g., protein, DNA, etc.) is punctate or smooth, fir example. Some intensity-based features also relate to texture. Sf4</p>
<p>f V -p $ I * V P P p U P 5 5 5 I U I P 5</p>
<p>I I I I qt U*</p>
<p>[00109] Intensity-based features also include features associated with granularity. Granularity refers to bright spots or granules typically found within a cell or some subcellular region. In some cases, granules found by image analysis represent intercellular organelles or other objects in images. Phenotypic features associated with granularity include number of granules, area of granules and intensity of granules. Extracting features associated with granularity from an image is described in U.S. Provisional Patent Application No. 60/757,597, filed January 9, 2006, titled GRANULARITY ANALYSIS IN CELLULAR PHENOTYPES, which is hereby incorporated by reference for all purposes.</p>
<p>[0090] In certain embodiments, obtaining feature values may first involve identifying the locations of the discrete cells in the image. This may be accomplished by segmentation. Segmentation can be performed by various techniques including those that rely on identification of discrete nuclei and those that rely on the location of cytopl asmic proteins or cell membrane proteins. Exemplary segmentation methods are described in [iS Patent Publication No. US-2002-0l4l63lAl of Vaisherg et al., published October 3, 2002, and titled "IMAGE ANAI.XSIS OF THE GOLGI COMPLEX," US Patent Publication No. US-2002-0154798..Al of Cong et al. published October 24, 2002 and titled "EXTRACTING SHAPE INFORMATION CONTAINED IN CELL IMAGES," and U.S. Provisional Patent Application No. 60/757,598, filed January 9, 2006, titled DOMAIN SEGMENTATION AND ANALYSIS, all of which are incorporated herein by reference for all purposes.</p>
<p>[0091] In one approach, individual nuclei are first located to identify discrete cells.</p>
<p>Any suitable stain for DNA or histones may work for this purpose. Individual nuclei can be identified by performing, for example, a thresholding routine on images taken at a channel for the nuclear marker. After the nuclei are identified, cell boundaries can then be determined around each nucleus. In one embodiment, a non-specific marker for proteins such as Alexa 647 is used with an appropriate algorithm to identify cell boundaries. The assays described below include a DNA marker and a non-specific marker that may be used to facilitate segmentation.</p>
<p>[0092] Many features are defined on a per cell basis. More precisely, the features extracted on a per cell basis are typically aggregated over multiple cells in an image and provided as a statistical representation across all cells; e.g., a mean value across it S</p>
<p>I I I S</p>
<p>I 5 II * * , , It I S I I I S I fII III all cells in an image. In some cases, features are extracted from a limited domain within or near a cell in an image. For example, features may be extracted from a region hounded by a nucleus (e.g., identified by segmentation based on DNA or histone signal), a region identified as granules (e.g., particular gradient and size limitations), a region identified as cell peripheral regions (e.g., regions within certain distances of defined cell edges), etc. There are various reasons why a feature might be extracted from a sub-region within a cell. For example, changes in actin within the canaliculae may be a manifestation of cholestasis. Because canaliculae are often associated with inter-cellular junctions and reside in peripheral regions of cells, it may be desirable to employ a feature based on actin signal limited to peripheral or contact regions of cells. Further, sometimes a feature canbe extracted most clearly when confined to a relatively thin layer of cytoplasm such as that which would be found overlying a cell nucleus. For example, some features pertaining to the texture or distribution of a cell component within the cytoplasm can be observed most clearly when taken from the portion of cytoplasm lying on top of a cell's nucleus.</p>
<p>[0093] Features defined within perimeter regions of cells may be particularly relevant to models of' hepatotoxicity and associated pathologies. Examples of' perimeter regions that may be employed include periphery regions, contact periphery regions, free periphery regions, and cell contact regions. These regions may be identified for the individual cells in the image. The periphery of a cell can be identified in the image as a subset of pixels inside the cell for which a mask with a predetermined size centered on each of the pixel covers at least one of the cell's boundary pixels. The contact periphery of a cell can be identified in the image as a subset of pixels inside the cell for which a mask with a predetermined size centered on each of the pixels covers at least one of the cell's boundary pixels and at least one boundary pixel of an adjacent cell. The free periphery of a cell can he identified in the image as a subset of pixels that are periphery pixels but not contact periphery pixels. Further discussion of these regions may be found in above-referenced U.S. Provisional Patent Application No. 60/757,598.</p>
<p>[0094] Many phenotypic features of interest are defined for or within nuclei or other organelles within cells, granules, and perimeter regions. Various pathologies may have signatures that are localized in the nuclei or cell perimeter regions for example.</p>
<p>a a a I I I * * * ** . II, lIt In such cases, it is desirable to consider phenotypic features from these regions. For example, certain conditions that interfere with cellular mitosis result in punctate or diffuse nuclei. Hence features such as the mean, standard deviation, and/or kurtosis of pixel intensity values located within a nuclei (identified by segmentation) can be useful in characterizing the condition of a cell with respect to a condition that interferes with mitosis.</p>
<p>100110] Examples of markers used arid a subset of features obtained in particular assays are given below. The list of features may represent a small subset of the Ièatures that are obtained across a group of assays, the total number of which (across all five assays in this example) is around 1500 in some embodiments. As indicated above, in certain embodiments the features listed define the dimensions of the multi-.dinieiisjonal space in which a distance from DMSO controls is calculated fur each well (e.g., as shown in Figure 4).</p>
<p>i1til'ubu1jisi [00111] One example assay uses a tuhulin marker (e.g., DM1-cx), an actin marker (e.g, fluorescently labeled phalloidiii), a DNA marker (e.g., Hoechst 33341) and a lion-specific cellular protein marker (e.g., Alexa 647 nm succinimidyl ester).</p>
<p>i'uhulin and actin are cytoskeletal proteins, changes to the morphology or intensity of which may indicate hepatoxicity, including one or more hepatotoxic pathologies.</p>
<p>Actin lines the canalicular structures which may be involved with bile transport.</p>
<p>DNA and non-specific protein markers may be employed to facilitate segmentation of images into regions occupied by discrete cells as well as regions occupied by nuclei within cells.</p>
<p>[00112] The following are a subset of features obtained in the actinltubulin assay. In one example, the distances of wells from DMSO control are calculated using this subset of features: mean area of the cells in the Image mean area of the nuclei in the image mean axis ratio of the cells in the image t S $ I I S S I * * I I I I * I I I Is, I,.</p>
<p>mean axis ratio of the nuclei in the image mean circular variance of the cells in the image mean kurtosis of the intensity of' the Alexa signal of the cells in the image mean kurtosis of the intensity of the Actin marker signal of the cells in the image mean skewness of the intensity of the Alexa signal of the cells in the image mean skewness of the intensity of the Actin marker signal of the cells in the image mean total intensity of the Alexa signal of the cells in the Image mean total intensity of the Actin marker signal of the cells in the image mean total intensity of the Actin marker signal in the contact periphery of the cells in the image mean total intensity of the Actin marker signal in the free periphery of the cells in the image [00113] Area may he determined from a pixel count within the boundary deteniiincd by segmentation (e.g. cell boundary or nucleus boundary). Axis ratio is calculated by fitting the cell or nucleus to an ellipse and calculating the ratio of the major and minor axes.</p>
<p>[00114] Circular variance represents the deviation of a particular shape or edge from a true circle. One goal is to distinguish elongated shapes from generally circular shapes. Shapes with a greater degree oi elongation will have a larger value of circular vanance. Briefly, circular vanance is calculated from a centroid of an object or edge under consideration. The centroid (X, Y) represents the coordinate of the mean value of X and the mean value of Y in the edge under consideration. Once the centroid of an edge or closed region is identified, the radii between the centroid and each edge or boundary point are calculated. From these radii, a mean radius value r0 is calculated for the edge under consideration. With this mean value and the individual radii, the circular variance can be calculated. Edges with a greater range in the value of their individual radii will give greater values of circular variance. Further discussion of this feature may be found in U.S. Patent Publication No. 20050273271 titled METHOD OF CHARACTERIZING CELL SHAPE, which is hereby incorporated by reference.</p>
<p>a I I I * * I * I I I I I a I I I I.. III [00115] Kurtosis and skewness of the intensity are denved from fourth and third (respectively) moments of an intensity distribution. As the feature name suggests, mean kurtosis of the intensity of a particular marker within the cells of an image is determined by calculating the kurtosis of the intensity of the marker within each cell and taking the mean over all cells in the image. Mean skewness is similarly calculated. Mean total intensity is also calculated by determining the total intensity of the marker per cell or cell region (i.e., the contact and cell peripheries described above) and taking the mean over all cells or regions in the image.</p>
<p>Example 2: BSEP/MRP2</p>
<p>[00116] A second example assay uses a marker for Bile Salt Transporter protein (BSEP), a marker for Multidrug Resistance Protein 2 (MRP2), a DNA marker and a non-specific cellular protein marker (e.g., the Alexa 647 marker). BSEP and MRP2 are transporter proteins believed to be relevant to hepatotoxicity because both localize in the canaliculae, where bile transport may occur. Transport of bile across the canalicular membrane is mediated by BSEP, and it is believed that drug-induced cholestasis may he caused by direct inhibition of the BSEP transporter. MRP2 transports bile salts, and inhibition of its activity may also result in intrahcpatic cholestasjs.</p>
<p>[00117] The following is a subset of features obtained in the BSEP/MRP2 assay. In one example, the distance of wells from DMSO control wells are calculated using these features: mean granular area of the BSEP marker signal of the cells of the image mean kurtosis of the intensity of the BSEP marker signal of the cells in the image mean number of granules in cells as indicated by the BSEP marker signal in the image mean moment lof the intensity of the BSEP marker signal of the cells in the image mean moment 2 of the intensity of the BSEP marker signal of the cells in the image mean skewness of the intensity of the BSEP marker signal of the cells in the image ::: ,: :: :: mean total intensity of the BSEP marker signal of the cells in the image mean total intensity of the BSEP marker signal in the contact penphery of the cells in the image mean total intensity of the BSEP marker signal in the free periphery of the cells in the image mean mean intensity of the BSEP marker signal of the cells in the image mean mean Intensity of the BSE1 marker signal in the contact penphery of the cells in the image mean mean intensity of the BSEP marker signal in the free periphery of the cells in the image mean total granular intensity of the BSEP marker signal of the cells of the image mean granular area of the MRP2 marker signal of the cells of the image mean kurtosis of the intensity of the MRP2 marker signal of the cells in the image mean number of granules in cells as indicated by the MRP2 marker signal in the image mean moment lof the intensity of the MRP2 marker signal of the cells in the image mean moment 2 of the intensity of the MRP2 marker signal of the cells in the image mean skewness of the intensity of the MRP2 marker signal of the cells in the image mean total mnlensity of the MRP2 marker signal of the cells in the image mean total intensity of the MRP2 marker signal in the contact periphery of the cells in the image mean total intensity of the MRP2 marker signal in the free periphery of the cells in the image mean mean intensity of the MRP2 marker signal of the cells in the image mean mean intensity of the MRP2 marker signal in the contact periphery of the cells in the image mean mean intensity of the MRP2 marker signal in the free periphery of the cells in the image mean total granular intensity of the MRP2 marker signal in the cells of the image [00118] Mean granular area in the BSEP signal of cells of the image is determined by identifying the granules in the BSEP signal, calculating the total area of the granules per cell, and taking the mean area across all cells in the image.</p>
<p>Similarly, number of granules and total granular intensity are determined by identi'ing the granules in the BSEP signal, and calculating the number of granules or total intensity of the granules on per cell basis and taking the mean across all cells.</p>
<p>I I I I</p>
<p>I * 0 II II I.. III [00119] Mean mean Intensity of the BSEP marker is calculated by taking the mean intensity of the marker on a per cell or cell region basis, and taking the mean of the mean intensity across all cells or regions.</p>
<p>[00120j Moment I and moment 2 are additional measures of the moments of the distribution. Moment I is calculated using the following: P, and moment 2 is calculated by p, - )2 ( -)2] where p is Intensity of a pixel at coordinates (x,, y) wthin an object (cell).</p>
<p>[00121 Other features (kurtosis, skewness, etc.) are as determined as discussed above with respect to the actin/tubulin assay.</p>
<p>nple 3: TGN/Cytochrome [00122] A third assay uses a Trans-Golgi Network (TGN) marker (e.g., TGN38), a cytochrome-c marker, a DNA marker and a lion-specific cellular protein marker (e.g., the Alexa 647 marker). The Golgi network transports bile in hepatocytcs. Its morphology is affected by bile transport. Hence, phenotypic features derived from markers for the trans-Golgi network are relevant to pathologies impacting (or impacted by) bile transport. Further, trafficking of the bile transporters BSEP and MRP2 occurs from the Golgi to the canalicular membrane, and disruption of this pathway may lead to alterations in Golgi morphology and intrahepatic cholestasis Cytochrome-c is located in the mitoehondrial matrix. Steatotic compounds affect lipid oxidation in the rnitochondrja. Inhibiting mitochondrial function may lead to an increase in intracellular neutral lipids and steatosis. Hence features derived from markers tbr mitochondrjal proteins such as cytochrorne-C may * : * * :.. .:. * * assist classifying stimuli inducing steatosis, cholestasis or other hepatotoxic pathologies.</p>
<p>[00l23J The following is a subset of features obtained in the TGN/cytochrorne-C assay. In one example, the distance of wells from DMSO control wells are calculated using these features: mean kurtosis of the intensity of the TGN marker signal of the cells in the image MOMENT I of the intensity oithe TGN marker signal of the cells in the image MOMENT2 of the intensity of the TGN marker signal of the cells in the image mean skewness of the intensity of the l'GN marker signal of the cells in the image mean total intensity of the TGN marker signal oithe cells in the image mean mean intensily of the TGN marker signal in the contact penphery of the cells in the image mean mean intensity of the FGN marker signal in the free penphery of the cells in the image mean mean intensity of the T(.iN marker signal of the cells in the image mean mean iiitensity of the l'( iN marker signal in the contact periphery olthe cells in the image mean mean intensity of the IGN marker signal in the free periphery of the cells in the image mean kurtosis of the intensity o!the cytochrorne-C marker signal of the cells in the image mean skewness of the intensity of Ihe cylochrome-C marker signal of the cells in the image mean total intensity of the cytochrome-C marker signal of the cells in the image mean mean intensity of the cytochrome-C marker signal in the contact periphery of the cells in the image mean mean intensity of the cytochrorne-C marker signal in the free periphery of the cells in the image mean mean intensity ol the cytochrome-C marker signal of the cells in the image mean mean intensity of the cytochrome-C marker signal in the contact periphery of the cells in the image mean mean intensity of the cytochrome-C marker signal in the free periphery of the cells in the image [00124] These features are calculated as discussed above.</p>
<p>: : : ; : I,. *l* I I</p>
<p>Example 4: BODIPY</p>
<p>[00125] A fourth assay uses a marker for lipids (e.g., BODIPY), a DNA marker arid a non-specific cellular protein marker. Excessive accumulation of lipids and/or certain lipid morphologies are associated with hepatotoxicity, for example, steatosis.</p>
<p>The following is a subset of features obtained in the BODIPY assay. In one example, the distance of wells from DMSO control wells are calculated using these features: mean granular area of the BODIPY signal of the cells of the image mean kurtosis of the intensity of the I3ODIPY signal of the cells in the image mean number of granules in cells as indicated by the BODIPY signal in the image mean total intensity of the J3ODIPY signal of the cells in the image mean mean intensity of the BODIPY signal of the cells in the image MOMENT! of the intensity of the BOl.)IPY marker signal of the cells in the image mean total granular intensity of the 13ODIPY signal in the cells of the image [00126] These features arc calculated as discussed above.</p>
<p>Example 5: TRITC-DHPE [00127] A fifth assay uses a fluorescently labeled phospholipid (e.g., TRITC- DHPE N-(6-tetram ethyirhodami nethiocarhamoyl)-I,2-dihexadecanoyl -sn-glycero-3 -phosphoethanolanijne, triethylammonium salt), a DNA marker and a non-specific cellular protein marker. Phosholipidosis is an accumulation of phospholipids in lysosomes as lamellar bodies. Drug-induced phosholipidosis in hepatocytes can be measured by imaging the accumulation of DHPE-TRITC in lysosomes. As phospholipids are affected by phospholipidosis and possibly other hepatocyte pathologies, the DHPE marker can provide features useful in classifying hepatotoxicity. The following is a subset of features obtained in the DHPE assay. In I I * I I I I * , * * * * * * one example, the distance of wells from DMSO control wells are calculated using these features: mean kurtosis of the intensity of the DHPE signal of the nuclei in the image mean total granular intensity of the DHPE signal of the cells of the image [00128] These features are calculated as discussed above.</p>
<p>[001 29] In the description of each of the above assays, a set of features was identified. These features define a multi-dimensional space within which results from tests employing compounds at a particular concentration (or more generally stimuli at particular levels) may be represented as single points. In the case where replicates are employed, a given compound/concentration has multiple points within this feature space. As explained previously, in certain embodiments, median values may he selected from among the data points produced from these replicates. Regardless or whether replicates are employed, a given compound/concentration data point may be assessed for "activity" by considering its position within the multi-dimensional phenotype space. As explained above, one measure of activity is a Euclidean distance from a central point in the feature space, which central point is associated little or no activity -e.g., the point representing a negative control produced by treating cells with DMSO or similar compound for example. Compound/concentrations producing data points separated by more than a "threshold" distance from the point of a negative control are deemed "active" and therefore made available for building a decision tree model or, in the reverse case, made available for classification by serving as inputs to such model. The threshold distances may be determined by empirically correlating level of activity (ability to induce pathology states) with nurnencal separation in the feature space.
In certain embodiments, a compound/concentration is deemed active if its distance from the negative control is greater than a threshold distance iii any assay (e.g., any of the five assays described above).</p>
<p>Model Examples</p>
<p>[001301 Examples of models built using methods described herein are provided below. The models were built using data fOr about 200 compounds, each annotated as a a I a I * I I I I * I I I II, III positive, negative or undefined for steatosis, cholestasis, phospholipidosis and hepatotoxicity. Multiple concentrations of each compound were applied to wells and the assays described above were pcrfbrmed. Distances from DMSO control wells were calculated fbr each well to identify the "active" wells using the features listed above. Features from one or more assays were then used to build models for each of the pathologies and overall hepatotoxicily Steatosis [00131] Steatosis is a liver disorder marked by the accumulation of an abnormally large amount of!it within liver hepatocytes. The additional fat collects in vesicles that can be either large or small; when the vesieles are large the condition is known as macrovesicular steatosis and otherwise the condition is known as microvesicular steatosis Steatosis is an important measure of liver function because the presence of steatosis can implicate a variety of serious medical conditions, such as hepatitis infection and liver disease due to chronic alcoholism.</p>
<p>[00132] In certai ii embod i nienis, coniputer-implernented methods of classifying a hepatocyte or population ol hepalocytes according to whether they exhibit steatosis are provided. In certain embodiments the methods involve (a) receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (b) using at least a first subset of the set of phenotypic hatures of the hepatoeyte or population of hepatocytes to determine whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype; (c) if the hepatocyte or hepatocytes is detennined in (b) to exhibit a phenotype that is significantly different from the negative control plieiiotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a model for classifying cells based on whether they exhibit steatosis; and (d) receiving a steatosis classification for the hepatocyte or population of hepatocytes as an output from the model.</p>
<p>[00133] Also provided are methods of producing a model for classifying hepatocytes according to a whether they exhibit steatosis, the method comprising: (a) receiving data points, each comprising (i) a set of phenotypic features of a hepatocyte</p>
<p>I V V</p>
<p>I I</p>
<p>I I</p>
<p>I., lIt or population of hepatocytes and (ii) and indication of whether steatosis is exhibited; (b) in a multi-dimensional phenotypic feature space, calculating a measure of (lifference, for each of the data points, between at least a first subset of the set of phenotypic features of the data point and corresponding phenotypic features of a negative control; (c) identifying those data points having measures of difference as calculated in (b) that are greater than a threshold value; and (d) using the data points identified in (c) to create a model for classifying hepatocytes according to whether they exhibit steatosis based on a second subset of the set of phenotypic features. In certain embodiments, the model is a decision tree. In certain embodiments, the model is an ensemble of decision trees. A decision tree model for steatosis may he produced by applying a random forest algorithm to the data points.</p>
<p>[00134] Models for steatosis may make use of various fCaturcs calculated within the boundaries of whole cells, nuclei, peripheral regions of' cells, as well as granules. Markers for lipids and proteins associated with canalicular structures may provide signal for various phenotypic features used as inputs for such models.</p>
<p>Examples of suitable neutral lipid markers include BOI)IPY (available from Invitrogen, Carlsbad, California) and Nile Red available from (available from liivitrogen, Carlsbad, California). Examples of markers for canalicular structures include markers for BSEP, MDR2, and actin, for example. As one manifestation of steatosis is an accumulation of lipid vesicles within the cell, signal emanating from lipid markers, particularly signal having some granular morphology may he the basis for one or more features employed in decision tree models for steatosis. Markers for cytochronic C (including labeled cytochrome C itself) may also be useful for mcasunng steatosis, which may be caused by inhibiton of' mitochondrial function.</p>
<p>100135] In one example, random forest models for the prediction of steatosis were built as described above using a combination of' all five assays described above.</p>
<p>Variable selection was performed using a measure of decrease in accuracy that the random forest algorithm provides (see, e.g., Leo Breiman, "Random Forests -Random Features," referenced above). The initial random fbrest model built using all five assays had 1481 features (independent variables). Successive models built based on the most important variables of the previous model had 1 03 and 13 variables, respectively. The vanables used in the 13 variable model follow: I I, , :_. *I ** *, average ratio of the intensity of the BSEP signal to the MRP2 signal in the periphery region of the live cells in the image mean granular area of the BODIPY signal of the cells of the image mean total granular intensity of the I3ODIPY signal in the cells of the image mean kurtosis of the intensity of the BODIPY signal of the nuclei in the image mean moment 1 of the intensity of the I3ODIPY signal of the contact periphery of the cells in the image mean number of granules in cells as indicated by the BODIPY signal in the image mean skewness of the intensity of the BO[)IPY signal of the nuclei in the image mean skewness of the intensity of the BOD1PY signal in the free periphery of the cells in the image mean standard deviation of the BODEPY signal of the nuclei in the image mean total intensity of the BODIPY signal in the contact periphery of the cells in the image mean total intensity of the BODIPY signal in the free periphery of the cells in the image mean total intensity of the BODII>Y signal in the periphery of the cells in the image [00136] As can be seen from this list of features, all but one variable resulting from variable selection is a BODIPY feature. As BODIPY is a dye that tags neutral lipids, it may be particularly useful to characterize steatosis. Granularity of the lipids in the cells (as indicated by the granular area, intensity of the granule signal, and number of granular features) plays a significant role in the model; this may be because lipid vesicles (granules) are a manifestation of steatosis. Texture of the lipids in various regions of the cells (e.g., indicated by standard deviation, kurtosis and skewness of the BODIPY (neutral lipid) signal in one or more cell regions) also plays a role in this embodiment. Standard deviation, kurtosis, skewness, moment I and moment 2 of the BODIPY signal within the nuclei may indicate changes in accumulation and distribution of the stain, such as formation of granules. Lipid accumulation in the cell peripheries, represented by total intensity and skewness of the intensity of BODIPY in the peripheries may also be important in classifying stimuli for inducing steatosis. In some embodiments, the markers from which the Es I I I I I I I TI I* , I phenotypic features are extracted include at least one marker for a neutral lipid and at least one marker for a phospholipid.</p>
<p>[00137] Features derived from non-lipid cell components can also he used in models fbr classifying cells/stimuli for steatosis. For example, features can be derived from one or more of a marker for a canalicular component, a marker for nuclear component, and a marker for general protein content within a cell. Further, as indicated, bile transport may also be important in characterizing steatosis. Thereibre markers such as markers for BSEP and MRP2 may he employed in feature sets for steatosis models. in some embodiments, the markers from which phenotypic features arc extracted include at least one marker for BSEP and at least one marker fbr MRP2.</p>
<p>In the specific example presented here, the ratio of BSEP to MRP2 is a 1ature used in steatosis models.</p>
<p>(holestasis [00138] Cholestasis is characterized as inhibition of bile flow caused by a wide variety of mechanisms that involve elements of the biliary tree, including bile ducts, ductules, the basolateral or canalicular membrane, the tight junctions or pericanalicular network of the hepatocytes, the ATPase, and transporters of the hepatocytes' basolateral and canalicular plasma membranes. It may involve defects of the transport of bile acids from the sinusoidal blood into hepatocytes or from hepatocytes into bile. Any of these elements and mechanisms may give rise to phenotypic features used in models for classifying stimuli or cells based on cholestasis.</p>
<p>[00! 39] In certain embodiments, computer-implemented methods of classifying a hepatocyte or population of hepatocytes according to whether they exhibit cholestasis are provided. In certain embodiments the methods involve (a) receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (h) using at least a first subset of the set of phenotypic features of the hepatocyte or population of hepatocytes to determine whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype; (c) if the hcpatocyte or hepatocytes is determined in (b) to exhibit a phenotype that is significantly * .1* 4 4I * * * I * I * * I I II 4 4 S 4 t I * : * * * * * * *II III S S S different from the negative control phenotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a model for classifying cells based on whether they exhibit cholestasis; and (d) receiving a cholestasis classification lbr the hepatocyte or population of hepatocytes as an output from the model [00140] Also provided are methods of producing a decision tree for classifying hepatocytes according to a whether they exhibit cholestasis, the method comprising: (a) receiving data points, each comprising (i) a set of phenotypic features of a hepatocyte or population of hepatocytes and (ii) and indication of whether cholestasis is exhibited; (b) in a multi-dimensional phenotypic feature space,calculating a measure of difference, for each of the data points, between at least a first subset of the set of phenotypic features of the (lata point and corresponding phenotypic features of a negative control; (c) identifying those data points having measures of difference as calculated in (h) that are greater than a threshold value; and (d) using the data points identified in (c) to create a model for classifying hepatocytes according to whether they exhibit cholestasis based on a second subset of the set of phenotypic features. In certain embodiments, the model is a decisioii tree. In certain embodiments, the mode! is an ensemble of decision trees A decision tree mode! for cho!estasis may be produced by applying a random forest algorithm to the data points.</p>
<p>[00141] Models for cholestasis may make use of various features calculated within the boundaries of whole cells, nuclei, peripheral regions of cells, as well as granules. In certain embodiments, at least one of the phenotypic features is extracted from segmented regions of the images corresponding to nuclei and/or peripheral regions of or within the cells. Cholestasis may be caused in some instances by damage to pencanalicular microhlaments Ior example, cytochalasin B has been shown to produce a prompt arrest of bile flow in rats, thereby resulting in cholestatic injury. In addition, phalloidin causes an increase in filarnentous F actin around canaliculi and tight junctions. Thus, changes in actin morphology or intensity features may be indicative of cholestatic injury. BSEP is the major bile salt transporter in the liver canalicular membrane. One of the physiological roles of MRP2 is to transport bilirubin glucuronides from liver into the bile. Thus, changes to BSEP and MRP2 may also be indicative of cholestatic injury. Further, the trans-Golgi network also *.* : :: :: t I I I S</p>
<p>I I I I I I</p>
<p>III III I I S</p>
<p>plays a role in bile transport within hepatocytes. Hence, markers for any of BSEP, MRP2 (or other bile transport proteins), and the TGN are sometime employed in features for cholestasis models.</p>
<p>[00142] In some models, at least one of the one or more markers comprises a marker for a bile transport protein, a marker for general protein content within a cell, or a marker for a cytoskeletal component. In certain embodiments, the one or more markers includes markers for a Golgi component, genera! protein content within a cell, and/or a cytoskeletal component. In certain embodiments, the one or more markers includes a marker for general protein content within a cell, a marker for a cytoskeletal component, and a marker fbr a nuclear component. Regarding phenotypic features, at least one of the features may characterize canalicular structures at the periphery of hepatocytes. In certain embodiments, at least OflC of the features is derived from markers for one or more of MRP2, BSEP, I'GN and cytochrome C. 1001431 Random forest models were built as described above using data from a combination of the Actin and BSEP/MRP2 assays, a combination of and the Actin and TGN/Cytochrome-C assays and the Actin assay alone. Variable selection was perlonned as discussed above for successive models. Sonic of the features used in the cholestasis models shown below are specific to live or dead cells. In certain embodiments, phenotypic features of cells obtained by the assay or assays may be used to determine if the cells are live or dead. See, e.g., the above-referenced patent applications US Patent Application No. 11/082,241, titled ASSAY FOR DISTINGUIShING LIVE AND DEAD CELLS and US Patent Appliction No. (Atty. Docket No. CYTOPI55XI) filed February 14, 2006 and titled ASSAY FOR DISTINGUISHING LIVE AND DEAD CELLS.</p>
<p>[00144] In one embodiment, the initial random forest model built using a combination of the Actin and BSEP/MRP2 assays had 973 features (independent variables). Successive models built based on the most important variables of the previous model had 145 and 21 variables, respectively. The variables used in the 21 variable model follow: S.. * a S * * * * S IS. . a.</p>
<p>a t a I I a I * S * S * I S * S * I S *.e a.</p>
<p>mean granular area of the Actin marker signal of the dead cells in the image mean kurtosis of the BSEP marker signal in the contact penphery of the dead cells in the image mean kurtosis of the intensity of the Alexa signal of the live cells in the image mean kurtosis of the intensity of the Actin marker signal of the nuclei in the live cells in the image mean kurtosis of the intensity of the Alexa signal of the cells in the image number of contact peripheries in the image number of granules in the dead cells as indicated by the MRP2 signal in the image mean perimeter of the contact pcnphery of the cells in the image mean RI of the contact periphery of the live cells in the image mean R2 of the contact periphery of' the live cells in the image mean SHARP of' the BSEP marker signal in the contact regions of the dead cells in the image mean SHARP of the Alexa signal in the nuclei of the live cells in the image mean skewness of the intensity of the Alexa signal of the live cells in the image mean skewness of the intensity of the Aclin marker signal in the contact periphery of the live cells in the image mean skewness of the intensity of the Alexa signal of the cells in the image mean skewness of the intensity of the Aetin marker signal in the contact periphery of the cells in the image mean skewness of the intensity of the Actin marker signal of nuclei in the image mean standard deviation of the intensity of the Hoechst signal in the dead cells of the image mean standard deviation of the Actin marker signal in the nuclei of the image mean total intensity of the hoechst signal in the dead cells of the image mean total intensity of the Hoechst signal in the nuclei of the dead cells in the image [00145] Ri and R2 are morphological features related to moment 1 and moment 2. Ri is calculated using the following expression: * . . I * * * C *t * I I II</p>
<p>C I I C I S</p>
<p>II C * * I C I I I.. III I I C and R2 is calculated using the following expression:</p>
<p>N</p>
<p> / -\2 / -\2 -yr,-x) +y,-yj where x and y are pixel coordinates within a segmented object, such as cell or cell component. Note that Ri and R2 are shape-based features; intensity need not be used in the calculation.</p>
<p>[00146] Sharp is a measure of the drop of the intensity at the edgy of an object.</p>
<p>It may be calculated using the following expression: ---edge(x,,y,) where N is the total number of edge pixels and edge(x1, y1) is obtained l)y the Marr-llildrcth edge detection operator.</p>
<p>[00147] Features based on the actin marker in the 21 variable model include granular area in the dead cells, Ri and R2, vanous features related texture including standard deviation, skewness and kurtosis of the intensity in the nuclei, skewness of the intensity in the contact periphery.</p>
<p>[00148] Features involving cellular protein (as marked by the Alexa marker in certain embodiments) and DNA (as marked by the Hoechst marker) are also Important in this model. Features that may characterize the texture of cellular protein include kurtosis and skewness of the Alexa (non-specific protein) intensity. I)NA-related features include intensity-related features of dead cells.</p>
<p>[00149] Only two BSEP/MRP2 features are provided among the 21 variables in the model: the number of MRP2 granules in the dead cells and SHARP of BSEP in the contact region. As mentioned, both BSEP and MRP2 are instrumental in the transport of bile within a cell; hence their role in some cholestasis models.</p>
<p>[00150] In another example, the initial random forest model built using a combination of the Actin and TGN/Cytochrome-C assays had 973 features (independent variables). Successive models built based on the most important * * : .. * * S IS * S I It I * I U S S * I * * I I I S * I. S *t. *I* variables of the previous model had 120 and 16 variables, respectively. The variables used in the 16 variable model follow' mean granular area of the Aclin marker signal of the dead cells in the image mean kurtosis of the intensity of the Alexa signal of the live cells in the image mean kurtosis of the Intensity of the Actin marker signal of the nuclei in the live cells in the image mean kurtosis of the intensity of the TGN marker signal of the periphery of the live cells in the image mean kurtosis of the Intensity of the Alexa signal of the cells in the image number of contact pcnpheries in the image mean RI of the contact periphery of the live cells in the image mean R2 of the contact PeriPhery of the live cells in the image mean SHARP of the Alexa signal iii the iiuclei of the live cells in the image mean SHARP of the IUN signal iii the nuclei of the live cells in the image mean skewness of the intensity of the Alexa signal of the live cells in the image mean skewness of the intensity ofihie l(N marker signal of the live cells in the image mean skewness of the intensity of the Alexa signal of the cells in the image mean total intensity of the Actin marker signal of the dead cells in the image mean total intensity oft he I-loechst signal of the dead cells in the image mean total intensity of the Hoechst signal in the nuclei of the dead cells in the image [00151] In yet another exaniple, the initial random forest model built using the Actin assay alone had 575 fiatures (independent variables). Successive models built based on the most important variables of the previous model had 79 and 10 variables, respectively. The variables used in the 10 variable model follow: mean kurtosis of the intensity of the Alexa signal of the live cells in the image mean kurtosis of the intensity of the DM I -ix signal in the nuclei of' the image : :1. :E; number of contact peripheries in the image mean RI of the Actin signal in the contact periphery of the live cells in the image mean R2 of the Actin signal in the contact periphery of the live cells in the image mean skewness of the intensity of the Alexa signal of the live cells in the image mean skewness of the intensity of the Alexa signal of the cells in the image mean skewness of the intensity of the Alexa signal in the nuclei of the cells in the image mean total intensity of the Hoechst signal of the dead cells in the image mean total intensity of the Hoechst signal in the nuclei of the dead cells in the image Phospholiidosjs 001 52] Another hepatotoxic pathology is phospholipidosis, a disorder that affects lipid storage, and particularly phospholipids. Phospholipids, which are structural components of mammalian cytoskeleton and cell membranes, accumulate in the cells. Phospholipid metabolism may be altered by (Irugs that interact with phospholipids or the enzymes that affect their metabolism. (ationic amphiphilic drugs (CADs), for example, may induce phospholipiclosis. Phospholipidosis may also afléct lysomsomal function. Lysosomes are subcellular organdies necessary for digestion of extracellular molecules, damaged or old cell parts aiid microorganisms.</p>
<p>Lysosomes play an important role in detoxification of waste products.</p>
<p>[001531 In certain embodiments, the features derived from granules within cells Rature prominently in models for phospholipidosis. Among such features are counts of lipid granules within hepatocytes, measures total lipid granule intensity within hepatocytes, and sizes of granules within hepatocytes (max, mean, etc.).</p>
<p>[00154] Tn certain embodiments, computer-implemented methods of classifying a hepatocyte or population of hepatocytes according to whether they exhibit phospholipidosis are provided. in certain embodiments the methods involve (a) receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (h) using at least a first subset of the set of phenotypic features of the hepatocyte or population of hepatocytes to determine whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype; (c) if the * I I.. * ** * : : * : : :.</p>
<p>* S I S S I * * I * * S I I I a.. Sal I I S hepatocyte or hepatocytes is determined in (b) to exhibit a phenotype that is significantly different from the negative control phenotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a mode! for c!assifying ce!!s based on whether they exhibit phospholipidosis; and (d) receiving a phospholipidosis classification for the hepatocyte or population of hepatocytes as an output from the model.</p>
<p>[00155] Also provided are methods of producing a model for classifying hepatocytes according to a whether they exhibit phospholipidosis, the method comprising: (a) receiving data points, each comprising (i) a set of phenotypic features of a hepatocyte or population of' hepatocytes and (ii) and indication of whether phospholipidosis is exhibited; (h) in a multi-dimensional phenotypic feature space, calculating a measure of difference, for each of the data points, between at least a first subset of the set of phenotypic features of the data point and corresponding phenotypic features of a negative control; (c) identifying those data points having measures of difference as calculated in (b) that are greater than a threshold value; and (d) using the data points identified in (c) to create a model for c!assifying hepatocytes according to whether they exhibit phospholipidosis based on a second subset of the set of phenotypic features. hi certain embodiments, the model is a decisioiì tree. In certain embodiments, the model is an ensemble of decision trees. A decision tree mode! for phospholipidosis may be produced by applying a random forest algorithm to the data points.</p>
<p>[00156] In certain embodiments, at!east one of the one or more markers is a marker for genera! protein content within a cell or a marker for a phospholipid. In some cases, the markers from which the phenotypic features are extracted include at least one marker for DHPE (e.g., TRITC-DHPE). The phenotypic features employed in phospholipidosis models may be extracted from segmented regions of images corresponding to one or more of nuc!ei, granules, and peripheral regions within the cells. In some embodiments, a first phenotypic feature is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cel!s, and a second phenotypic feature is extracted from segmented regions of the images corresponding to nuclei within the cells. :.</p>
<p>S * S S I I I * * I S S :.. *. * [00157] Random forest models were built as described above using the DHPE-TRITC assay alone. (An example of another assay for phospholipidosis is described in U.S. Provisional Patent Application No. 60/759,130 filed January 12, 2006, which is hereby incorporated by reference). Variable selection was perft)rmed as discussed above for successive models. The initial random forest model built assays had 189 features (independent variables). Successive models built based on the most important variables of the previous model had 20 and 5 variables, respectively. The variables used in the 20 variable model follow: mean granular area of the DHPE signal of the live cells in the image mean skewness of the intensity of the DI-IPE signal of the nuclei in the image mean kurtosis of the intensity of the DHPE signal of the nuclei in the image mean kurtosis of the intensity of the DHPE signal in the contact periphery of the cells in the image mean total granular intensity of the DHPE signal in the cells of the image mean SHARP of the DHPE signal of the nuclei in the image mean skewness of the intensity of the Alexa signal of the cells in the image mean skewness of the intensity of the DHPE signal in the free periphery of the cells in the image mean standard deviation of the intensity of the DHPE signal in the contact periphery of the cells in the image mean skewness of the intensity of the DHPE signal in the cell contact regions in the image mean skewness of the intensity of the DHPE signal of the cells in the image mean number of granules in cells as indicated by the DI IPE signal in the image mean kurtosis of the intensity of the DHPE signal in the periphery of the cells in the image mean kurtosis of the intensity of the DHPE signal of the cells in the image mean standard deviation of the intensity of the DHPE signal in the periphery of the cells in the unage mean kurtosis of the intensity of the DHPE signal in the cell contact regions in the image mean skewness of the intensity of the DHPE signal in the periphery of the cells in the image mean standard deviation of the intensity of the DI-IPE signal of the cells in the image I I *I* I St * t: : :.</p>
<p>I * S S S I I S. I S S I S I * III * S S mean skewness of the intensity of the DF1PI signal in the contact periphery of the cells in the image mean standard deviation of the intensity of the 1)1-IPE signal of the nuclei in the image [00158] The first five features of those listed above were the variables used in the five variable model.</p>
<p>Hepatotoxicity Model [00159] A stimulus applied to cells may he classified as hepatotoxic based on whether the stimulus induces a generic perturbation of the hepatocyte phenotype.</p>
<p>Models for liepatotoxicity should he distinguished from models for specific pathologies such as cholestasis or steatosis. A perturbation classified as a hepatotoxic response may he a manifestation of any one or more pathologies including steatosis, phospholipiclosis, cholestasis necrosis, carcinoma, PPAR, etc. Features from various assays may be used in an overall hepatotoxicity model. In a specific example described herein, hepatotoxicity models were built using a combination of the BSEP/MRP2, BODIPY and Dl IPE assays and a combination of the BSEP/MRP2 and BODIPY assays.</p>
<p>[00160] Vanous markers or combinations of markers may be employed in features used for models for hcpatotoxicity. In certain embodiments, at least one of the markers is a marker for a cytoskeletal protein or structure, a marker for a canalicular component, a marker ftr an endocytic component, a marker for a mitochondrial component, a marker for nuclear component, a marker for a Golgi component, a marker fOr general protein content within a cell, or a marker for a lipid (neutral or phospholipid). In certain embodiments, the markers include markers for different types of lipids such as at least one marker for a neutral lipid and at least one marker for a phospholipmd. In some embodiments, the markers include markers for two or more proteins associated with bile transport such as at least one marker for BSEP and at least one marker fbr MRP2. Note that the features employed in models for hepatotoxicity may be calculated within various boundaries identified by I I III I If * : : . : : :.</p>
<p>I * I I I I * * I I I I I I.. lit I I I segmentation. Such boundaries may correspond to whole cells, nuclei, peripheral regions of' cells, and/or granules.</p>
<p>{OOl6l] An initial random forest model built using a combination of the BSEP/MRP2, BODIPY and DHPE assays had 868 features (independent variables).</p>
<p>Thus, certain embodiments employ marker sets including at least markers fbr a neutral lipid, a phospholipid, arid a bile transport protein. Other markers that may he included in this group include markers for a nuclear component and whole cellular protein. Successive models built based on the most important variables of the previous model had 172 and 29 variables, respectively. The variables used in the 29 variable model follow: mean granular area of the BODIPY signal of the cells in the image mean granular area of tile DHPE signal of the cells in the image mean total granular intensity of the BSEP marker signal of the live cells of the image mean total granular intensity of the BODIPY signal of' the cells of' the image mean t(.)tal granular intensity of the BSEP marker signal of the cells of I lie image mean total granular Intensity of the DHPE signal of the cells of' the Image mean kurtosis of the intensity of the Hoechst signal of the nuclei oI'lhe live cells in the image mean kuriosis of the Intensity of the Alexa signal of the live cells in tiìe image mean kurtosis of the intensity of the BODIPY signal in the contact periphery of the cells in the image mean kurtosis of tile intensity of the DH1E signal in tile contact periphery of' tile cells in the image mean kurlosis of the intensity of the BOD1PY signal of the nuclei of the cells in the image mean kurtosis of the intensity of' the Hoechst signal of tile nuclei of' the cells in the image mean major axis of the nuclei of the live cells in the image mean major axis of the nuclei in the image mean mean intensity of the MRP2 marker signal in the periphemy of the live cells in the image mean mean intensity of the Hoechst signal of the nuclei in the image mean mnomentl of the BODIPY signal of the nuclei in the image number of "fuzzy" nuclei in the image based on Hoechst signal t 4 II 4 I 4 * 4 41 * I I *I 4 4 I I I I : *,.</p>
<p>4I4 III number of cell contact regions of the live cells in the image number of contact penpheries of the live cells in the iniage number of cell contact regions in the image mean number of granules in live cells as indicated by the BSEP marker signal in the image mean number of granules in cells as indicated by the BODIPY signal in the image mean number of granules in cells as indicated by the BSEP marker signal in the image mean SHARP of the BSE1 marker signal in the nuclei of the cells in the image mean skewness of the intensity of the BODIPY signal of the nuclei in the image mean standard deviation of' the intensity of the hoechst signal of the live cells in the image mean standard deviation of the intensity of the MRP2 signal of the live cells in the image mean standard deviation of the intensity of the BODIPY signal of the nuclei in the image [00162] Note that an object is deemed to be "fuzzy" if the sharpness of the marker mask (e.g., DNA or 1loechst signal) is below a defined threshold. At least some of the "fuzzy" cells are dead and therefore have diffuse DNA staining.</p>
<p>[00163] Another initial random forest model built using a combination of the BSEP/MRP2 and BODIPY assays only had 815 features (independent variables), Successive models built based on the most important variables of the previous model had 140 and 23 variables, respectively. The variables used in the 23 variable model follow: mean granular area of the BODIPY signal of the cells in the image mean total granular intensity of the BSEP marker signal of the live cells of the image mean total granular intensity of the BODIPY signal of the cells of the image mean total granular intensity of the BSEP marker signal of the cells of the image mean kurtosis of the intensity of the BSEP marker signal in the contact periphery of the live cells in the image mean kurtosis of the intensity of the Hoechst signal in the nuclei of the live cells in the image mean kurtosis of the Intensity of the BODLPY signal in the nuclei of the cells in the image mean kurtosis of the intensity of the Hoechst signal in the nuclei of the cells in the image V $ ,f, fT ; ; , : :</p>
<p>V T S S I S</p>
<p>I S I * I I I IS. III I I I mean major axis of the nuclei in the image mean mean intensity of the Hoechst signal of the live cells in the image mean momenti of the intensity of the BODIPY signal of the nuclei in the image number of "fuzzy" nuclei in the image based on Hoechst signal number of cell contact regions of the live cells in the image number of contact peripheries of the live cells in the image mean number of granules in live cells as indicated by the BSEI marker signal in the image mean number of granules in cells as indicated by the BODIPY signal in the image mean number of granules in cells as indicated by the BSEP marker signal in the image mean SFIARP of the BSEP marker signal in the nuclei of the cells in the image mean skewness of the intensity of the MRP2 marker signal of the nuclei iii the image mean skewness of the intensity of the BODIPY signal of the nuclei in the image mean standard deviation of the intensity of the Hoechst signal of the live cells in the image mean standard deviation of the intensity of the BODIPY signal of the nuclei in the image [00164] As illustrated in the above examples of hepatotoxicity models, lipid features may be taken within granule regions, nuclear regions, and cell peripheral regions. Features taken from bile transport proteins may likewise be taken within granule regions, nuclear regions, and cell peripheral regions. Further, some features are taken only from cells characterized as live cells. Some of these features are based on morphology. Others are based on intensity of signal or texture.</p>
<p>IMAGE CAPTURE AND IMAGING APPARATUS</p>
<p>[00165] The assays described herein can be earned out in many dilièrent apparatuses. Generally, the cell samples are provided as discrete cell cultures on one or more support structures. Depending on the type of support structure, the cells may grow in two-dimensions or three-dimensions. Examples of support structures include bare plastic supports that include nutrients, glass surfaces, extra-cellular matrices such as collagen or Matrigel (available from BD Biosciences, San Jose, California), etc. q $t $ t</p>
<p> I I I</p>
<p>I I I I U I!</p>
<p>I U I U U I I</p>
<p>I U I U U I I U</p>
<p>11$ I U Such structures can be provided in multiwell plates, such as 24-, 96-, or 384-well assay plates (e.g., Costar plates (Corning Life Sciences, New York, New York) among others). An assay plate is a collection of wells arranged in an anay with each well holding multiple cells which are exposed to a stimulus or which provide a control sample. In other embodiments, single sample holders can be used instead of multi-well plates. Suitable culturing conditions and protocols for hepatocytes are described in US Patent Publication No. 20050014217.</p>
<p>[00166] Figure 8 shows a schematic block diagram of an image capture and image processing system 880 which can he used to capture and process the images of cells and store cell counts, phenotypic data, and other information used in assays of this invention. This diagram is merely a non-limiting example. The depicted system includes a computing device 882, which is coupled to an image processor 884 and is coupled to a database 886 The image processor receives information from an image-capturing device 888, which includes an optical device for magnifying images of cells, such as a microscope. i'he image processor and image-capturing device can collectively be referred to as the imaging system herein. The image-capturing device obtains information from a plate 890, which includes a plurality of wells providing sites fOr groups of cells. l'he computing device 382 retrieves the information, which has been digitized, from the image-processing device and stores such information into the database 886.</p>
<p>[00167] A user interface device 892, which can he a personal computer, a work station, a network computer, a personal digital assistant, or the like, is coupled to the computing device. In the case of cells treated with a fluorescent marker, a collection of such cells is illuminated with light at an excitation frequency from a suitable light source such as a halogen-lamp, arc lamp or laser (not shown). A detector part of the image-capturing device is tuned to collect light at an emission frequency. Preferably this is a digital camera that is sensitive to light over a wide range of frequencies. One may use emission filters to control which light wavelengths hits the camera.</p>
<p>Examples of suitable cameras are the Orca-100 from 1-lamarnatsu (Hamamatsu City, Japan) or the COOISNAPHQ FM from Roper Scientific. The collected light is used to generate an image that highlights regions of high marker concentration.</p>
<p>* * *.. * .* * * St I * S S * S I * I IS * . S I I I S * I I S I I S I IS. III S I [00168] The apparatus also includes a fluidics system for providing fluid to individual cell samples on the support. Such system canbe employed to deliver a compound or other treatment to individual cell samples and to perform wash out on individual cell samples separately. An example is the fluidics system on the live cell imaging addition of the Axon ImageXpress (Axon Instruments/Molecular Devices Corporation, Union City, CA).</p>
<p>[001 69] In one embodiment individual pipettes are provided for the individual wells of a support. Metered doses of a compound under investigation or a washing fluid are provided to each of the individual wells or to groups of individual wells as described above. The fluidics control system preferably allows precise control of the drug wash off timing and flow conditions. In certain embodiments, a key is to ensure thorough exchange of the compound, without also dislodging viable cells. And in some cases, it may be desirable that no cells, even dead cells, be washed away. So precise control of fluid force and turbulence can he important. To this end, the fluidics control system preferably allows fine control of fluid flow rates, delivery times, aspiration rates, and separation distance of the pipette or other delivery nozzle froni the wells. A flexible fluidics system is desirable in any apparatLis that is used to carry out different types of assay, as some treatments are more (Iifficuh to wash away than other, and some cells are more sensitive to wash out conditions than others. In situations where the cells are extremely sensitive and the treatment is difficult to remove, the apparatus may include a semipermeable covering over the individual cell samples, to allow washing fluid to penetrate to the cells but prevent the cells themselves from being washed away.</p>
<p>1.001701 The apparatus may also allow careful control of illumination conditions. Obviously when fluorescent markers are used the apparatus must he able to illuminate at appropriate excitation frequencies and capture radiation at the signature emission frequencies. However, it may also he important to ensure that the illumination conditions do not kill cells. Phototoxicity is a consideration. In a time-lapse assay, imaging parameters to be optimized include the intensity of illumination (which may dictate magnification) and the frequency at which individual images are captured. Again, different types of cells and different treatment regimens lead to * . .11 I II * S II * S S * S * * * U II * S * e I U S * S S * I I I U III *t* I S * different levels of sensitivity. So systems allowing flexible illumination conditions are generally preferred.</p>
<p>[00171] Other apparatus features include, optionally, mechanisms for controlling the environment in which the cells grow. Thus, the apparatus may include sub-systems for monitoring and controlling temperature and the atmospheric composition (e.g., carbon dioxide levels).</p>
<p>IMAGE PROCESSING AND ANALYSIS</p>
<p>[00172] As indicated, the images used as the starting point for the methods of this invention are obtained from cells that have been specially treated and/or imaged under conditions that contrast the cellular components of interest with other cellular components and the background of the image. These images may he processed in an automated manner employing image analysis software.</p>
<p>[001731 The individual images are processed using, for example, image correction and image processing techniques in order to extract the appropriate cellular features. Initially, the images can be corrected to remove artifacts introduced by the image capture system and to remove background. As an alternative to correction, "quality control algorithms" may be employed to discard image data based on, for example, poor exposure, focus failures, foreign objects, and other imaging failures. In one embodiment, problem images can be identified by abnormal intensities and/or spatial statistics.</p>
<p>[001741 In a specific embodiment, a correction algorithm may correct for changing light conditions, positions of wells, etc. In one example, a noise reduction technique such as median filtering is employed. Then a correction for spatial differences in intensity may be employed. The spatial correction may comprise a separate model for each image (or group of images). These models may be generated by separately summing or averaging all pixel values in the x-direction for each value of y and then separately summing or averaging all pixel values in the y direction for each value of x. In this manner, a parabolic set of correction values is generated for the image or images under consideration. Applying the correction values to the image * S *tS * ** * . S. S I S I * S I I * S* * * . S S S S * S S I I I I I Ste SS. I I adjusts for optical system non-linearities, mis-positioning of wells during imaging, etc. Note that different correction techniques and quality control algorithms can be carried out depending on the type of imaging that is used, e.g brightfield, con lbcal or deconvolution.</p>
<p>[00175] After image correction, a segmentation process is earned out to identify individual objects within the images. If these objects represent single cells, they can be counted to give cell counts at the various phases of the process as described above. Generally, segmentation allows feature extraction on a cell-by-cell basis. Segmentation identifies discrete regions of an image that include only those pixels where the components of a single cell are deemed to he present. Thus, each representation resulting from segmentation is a bounded collection of pixels associated with one or more features characterizing a single cell.</p>
<p>[00176] Segmentation can be accomplished in numerous ways as indicated elsewhere herein. These include use of watershed algorithms and techniques that identify separate nuclei. In many cases, the segmentation process identifies "edges' (locations in the images where there is a sudden change in pixel intensity) and then looks for closed connected edges in order to identify an object.</p>
<p>[00177] At every combination of dose and compound, one or more images are obtained. As indicated, these images are used to extract various parameter values for cellular features of relevance to a biological phenomenon of interest. Generally a given image of a cell, as represented by one or more markers, can be analyzed in isolation or in combination with other images of the same cell (as provided by different markers), to obtain any number of image features.</p>
<p>[00178] It will be appreciated that any simple or complex cellular feature than can be derived from the images is suitable for use in the present invention and that the invention is not to be limited to the specific examples given, nor to the specific sequence of actions, which is merely by way of an illustrative example. The result of this processing can be thousands or tens of thousands of cellular features derived from each of the treated wells and control wells.</p>
<p>* . .If * I. * I II I * I I</p>
<p>I I I I I II</p>
<p>* I I S I S I * I I I I S S I III II* S S I [00179] After the features have been extracted from the image they may be stored in database 386, and analysis of the features is carried out in order to assess the effect of the treatment on the cells [00180] In genera!, cells from a well are evaluated and some statistics for that well, e g. the averages of various properties, are calculated. In some cases, the same quantity is obtamed for replicate wells (e.g., the other five wells when the experiment is replicated six times) and statistics are computed on those statistics for the replicate wells in order to aggregate (e g. obtain the median of the average value mentioned above). However, averaging is not necessary and instead cell level information can be used, and have all further computations to he based on cell level information.</p>
<p>Hence, for each compound/dose/cell line/time point/marker set/etc. there would be thousands of data points.</p>
<p>[00181] In assays of this invention, it may be desirable to characterize the effect of the stimulus as a function of the dose or level of that stimulus. Cell counts and various phenotypic traits may be analyzed as a function of concentration (or other level of stimulus). When replicates or multiple cell lines are used, an average simple cellular feature can be obtained fur each cell line at each dose level. However, it is not necessary to calculate averages over cells. Also, other statistical measures can be used such as the median, specific quantiles, and standard deviations. Further, the statistical properties need not be calculated over all cells, hut can be calculated over a sub-population of cells, fur example over the sub-group of interphase cells, or the sub-group of cells that are arrested in mitosis for a period of time prior to compound wash out (e.g., 3-4 hours) In that case, a cell cycle related classification of the cells is carried out prior to summarizing or averaging the cell feature values.</p>
<p>[00182] The characterization of the stimulus (in terms of cell count, morphological effects, etc.) is sometimes referred to as a "path" or "response curve." Mathematically, the path is made up of multiple points, each at a different level of the stimulus. Each of these points is comprised of one or more parameters describing some aspect of a cell or collection of cells. In the sense that each point or signature in the path may contain more than one piece of information about a cell, the points may be viewed as arrays, vectors, matrices, etc Individual stimulus-response paths can be compared based on similarity of trajectory, distance between paths or segments p ft * p pp I P p p</p>
<p>I I I P I II</p>
<p>P P I P I I P</p>
<p>* I I I I P I I I.. *I* p I I thereof. In one example, the dose response can be compared across multiple cell lines, with each cell line providing its own dose-response path. Such comparisons provide meaningful information about drug selectivity, potency, mechanism of action, etc. [00183] One biological classification having application in this invention is whether a cell is alive or dead, and particularly whether a cell is apoptotic or not.</p>
<p>Apoptotic cells may be identified by various techniques. Apoptosis is characterized by a pathway that includes changes in certain membrane proteins, depolanzation of the rnitochondrjal membrane, release of cytochromc C from mitochondria, condensation, fragmentation and granularization of the nuclei, and breakdown of various nuclear and cellular proteins including actin, and mnicrotuhules. Many of these manifestations can be identified by image analysis. Examples include exposure of phosphatidyl serines on membrane proteins, the migration of cytochrome c from the mitrochondria into other regions of the cell, changes of mitochondrial membrane potential, and condensation, fragmentation and granularization of the nuclei.</p>
<p>001 84] In certain embodiments, cells under investigation are cultured with a marker that selectively penetrates into dead cells (and is excluded from live cells), where it marks one or more features in the cytoplasni and/or nucleus An example of such marker is propidiumn iodide, which penetrates the membrane of only those cells that have died.</p>
<p>[001 85] Another property of cells undergoing apoptosis is that they tend to become loosely attached to a substrate. Both cytoplasm shrinkage and loss of attachment may be a result of cytoskeleton damage by caspases. [his property can be detected by exposing the culture to a treatment that will tend to dislodge and remove loosely attached cells. As indicated, some embodiments of the invention employ careful washing to accomplish this. The level of apoptosis has been found to correlate well to a "washout coefficient" based on cell counts in washed and unwashed cultures exposed to a stimulus suspected of inducing apoptosis; e.g, (cc (unwashed) -cc(washed))/cc(unwashed).</p>
<p>COMPUTATIONAL SYSTEMS</p>
<p>* , *** , I, * , Is I * I</p>
<p>I I I I II</p>
<p>* I I I I I I * S I I I I I I II. lit S I I [00186] Methods, devices, systems and apparatus provided herein can he implemented in digital electronic circuitry, or in computer hardware, firmware, software, or in combinations of them. Apparatus can be implemented in a computer program product tangibly embodied in a machine-readable storage device for execution by a programmable processor; and aspects of the methods provided can be performed by a programmable processor executing a program of instructions to perform, e.g., clustering training set data, generating random forest models from clusters of training set data, operating on input data (e.g., images in a stack), extracting cellular phenotypic features from images, predicting outcomes and/or classifying responses (e.g., mechanisms of action for certain compounds) using models having as inputs phenotypic characteristics of cells, identifying cellular boundary regions, and other processmg algorithms.</p>
<p>[00187] Methods provided herein can be implemented in one or more computer programs that are executable on a programmable system including at least one programmable processor coupled to receive data and instructions from, afl(! to transmit data and instructions to, a data storage system, at least one input device, and at least one output device. Each computer program can he implemented in a high-level procedural or object-onented programming language, or in assembly or machine language if desired; and in any case, the language can be a compiled or interpreted language. Suitable processors include, by way of example, both general and special purpose microprocessors. Generally, a processor will receive instructions and data from a read-only memory and/or a random access memory. Generally, a computer will include one or more mass storage devices for storing data files; such devices include magnetic disks, such as internal hard disks and removable disks; magneto-optical disks; and optical disks. Storage devices suitable for tangibly embodying computer program instructions and data include all forms of non-volatile memory, including by way of example semiconductor memory devices, such as EPROM, EEPROM, and flash memory devices; magnetic disks such as internal hard disks and removable disks; magneto-optical disks; and CD-ROM disks. Any of the foregoing can be supplemented by, or incorporated in, ASICs (application-specific integrated circuits).</p>
<p>* I II I I I I I I I * 1</p>
<p>I I I I I I</p>
<p>* . I I I I I *I, III I I I [00188] To provide for interaction with a user, methods can be implemented on a computer system having a display device such as a monitor or LCD screen for displaying information to the user. The user can provide input to the computer system through various input devices such as a keyboard and a pointing device, such as a mouse, a trackball, a microphone, a touch-sensitive display, a transducer card reader, a magnetic or paper tape reader, a tablet, a stylus, a voice or handwriting recognizer, or any other well-known input device such as, of course, other computers. The computer system can be programmed to provide a graphical user interface through which computer programs interact with users.</p>
<p>[00189] Finally, the processor optionally can he coupled to a computer or telecommunications network, for example, an Internet network, or an intranet network, using a network connection, through which the processor can receive information from the network, or might output information to the network in the course of performing the above- described method steps. Such information, which is often represented as a sequence of instructions to be executed using the processor, may be received from and outputted to the network, for example, in the form of a computer data signal embodied in a carrier wave. The above-described devices and materials will be familiar to those of skill in the computer hardware and software arts.</p>
<p>[00190] It should be noted that methods and other aspects provided may employ various computer-implemented operations involving data stored in computer systems. These operations include, but are not limited to, those requiring physical manipulation of physical quantities. Usually, though not necessarily, these quantities take the thrm of electrical or magnetic signals capable of being stored, transferred, combined, compared, and otherwise manipulated. The operations described herein that may fbrm part of the methods described are useful machine operations. The manipulations performed are often referred to in terms, such as, producing, identifying, running, determining, comparing, executing, downloading, or detecting. It is sometimes convenient, principally for reasons of common usage, to refer to these electrical or magnetic signals as bits, values, elements, variables, characters, data, or the like. It should remembered however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities.</p>
<p> * * * * I I * I I I S.. 115 I I I [00191] Also provided are devices, systems and apparatus for performing the aforementioned operations. The system may be specially constructed for the required purposes, or it may be a general-purpose computer selectively activated or configured by a computer program stored in the computer. The processes presented above are not inherently related to any particular computer or other computing apparatus. Various general-purpose computers may be used with programs written in accordance with the teachings herein, or, alternatively, it may he more convenient to construct a more specialized computer system to perfhrm the required operations.</p>
<p>[00153] The above discussion has focused on hepatocytes and hepatotoxic responses. However, the description provided herein extends beyond hepatotoxicity to toxicity and pathologies in a variety of other cell lines, cell types, and tissues.</p>
<p>[00192] Although the above has provided a general description according to specific processes, various modifications can be made without departing from the scope of the description provided. Those of ordinary skill in the art will recognize other variations, modifications, and alternatives.</p>
Claims (78)
- <p>4 I * I I I I a * I I I S S * I a S I.. I*S I</p><p>CLAIMS</p><p>1. A computer implemented method of classifying a hepatocyte or population of hepatocytes according to whether it exhibits steatosis, the method comprising: (a) receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (h) using at least a first subset of the set of phenotypic features of the hepatocyte or population of'hepatocytes to determine whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype; (c) if the hepatocyte or hepatocytes is determined in (b) to exhibit a phenotype that is significantly different from the negative control phenotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a model for classifying cells based on whether they exhibit steatosis; and (d) receiving a steatosis classification ibr the hepatocyte or population of hepatocytes as an output from the model.</p><p>
- 2. The method of claim 1, further Comprising obtaining the set of phenotypic features of the hepatocyte or population of hepatocytes by automated image analysis of hepatocytes exposed to a stimulus.</p><p>
- 3. I'he method of claim 2, wherein the stimulus comprises exposure to a compound suspected of inducing steatosis.</p><p>
- 4. The method of claim 1, wherein determining in (b) whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly dii I erent from a negative control phenotype comprises: (i) in a multi-dimensional phenotypic feature space, calculating a measure of difference between at least a first subset of the set of phenotypic features of the hepatocyte or population of hepatocytes and corresponding phenotypic features of the negative control; and (ii) determining that the measure of difference calculated in (i) is greater than a threshold value.</p><p>
- 5. The method of claim I, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytes.</p><p>* I I I I I</p><p>I I I I I I</p><p>I * I * I I.. III
- 6. The method of claim 1, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>
- 7. The method of claim 1, wherein the set of phenotypic features is derived from at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>
- 8. The method of claim I, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP.</p><p>
- 9. The method of claim 1, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree.</p><p>
- 10. A computer implemented method of producing a model for classifying hepatocytes according to a whether they exhibit steatosis, the method comprising: (a) receiving data points, each comprising (i) a set of phenotypic features of a hepatocyte or population of hepatocytes and (ii) an indication of whether steatosis is exhibited; (b) in a multi-dimensional phenotypic feature space, calculating a measure of difference, for each of the data points, between at least a first subset of the set of phenotypic features of the data point and corresponding phenotypic features of a negative control; (c) identifying those data points having measures of difference as calculated in (b) that are greater than a threshold value; and (d) applying an algorithm to the data points identified in (c) to thereby create a model for classifying hepatocytes according to whether they exhibit steatosis based on a second subset of the set of phenotypic features.</p><p>
- 11. The method of claim 10, wherein the phenotypic features are obtained automatically by image analysis.</p><p>
- 12. The method of claim 10, wherein the measure of difference calculated in (b) is a Euclidean distance or a Manhattan distance.</p><p>
- 13. The method of claim 10, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytes.</p><p>I * * * I I I * * U U * I * I * I * Ut, III
- 14. The method of claim 10, wherein the set of phenotypic features comprises at least one feature charactenzing canalicular structures at the periphery of hepatocytes.</p><p>
- 15. The method of claim 10, wherein the set of phenotypic features is derived from at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>
- 16. The method of claim 10, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP.</p><p>
- 17. The method of claim 10, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree.</p><p>
- 18. The method of claim 10, wherein applying an algorithm to the data points to thereby create a model comprises applying a random forest algorithm to the data points.</p><p>
- 19. A computer program product comprising a machine readable medium on which is provided program instructions for classifying a hepatocyte or population of hepatocytes according to whether it exhibits steatosis, the instructions comprising: (a) code for receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (b) code for determine whether the l1epatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype using at least a first subset of the set of phenotypic features of the hepatocyte or population of hepatocytes; (c) code for, if the hepatocyte or hepatocytes is determined in (b) to exhibit a phenotype that is significantly different from the negative control phenotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a model for classifying cells based on whether they exhibit steatosis; and (d) code for receiving a steatosis classification for the hepatocyte or population of hepatocytes as an output from the model.</p><p>
- 20. The computer program product of claim 19, further comprising code for obtaining the set of phenotypic features of the hepatocyte or population of hepatocytes by automated image analysis of hepatocytes exposed to a stimulus.</p><p>I * I I I * I * . I I I S I.. III I I
- 21. The computer program product of claim 19, wherein the stimulus comprises exposure to a compound suspected of inducing steatosis.</p><p>
- 22. The computer program product of claim 19, wherein code for determining in (b) whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype comprises (i) code for, in a multi-dimensional phenotypic feature space, calculating a measure of difference between at least a first subset of the set of phenotypic latures of the hepatocyte or population of hepatocytes and corresponding phenotypi c features of the negative control; and (ii) code for detenmning that the measure of difference calculated in (i) is greater than a threshold value.</p><p>
- 23. The computer program product of claim 19, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytcs.</p><p>
- 24. l'he computer program product of claim 19, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>
- 25. The computer program product of claim 19, wherein the set ofphenotypic features is derived from at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>
- 26. The computer program product of claim 19, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP.</p><p>
- 27. The computer program product of claim 19, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree.</p><p>
- 28. A computer program product comprising a machine readable medium on which is provided program instructions for producing a model for classifying hepatocytes according to a whether they exhibit steatosis, the instructions comprising: (a) code fbr receiving data points, each comprising (i) a set of phenotypic features of a hepatocyte or population of hepatocytes and (ii) an indication of whether steatosis is exhibited; I * I I * I I I I I I.. III S I (b) code for, in a multi-dimensional phenotypic feature space, calculating a measure of difference, for each of the data points, between at least a first subset of the set of phenotypic features of the data point and corresponding phenotypic features of a negative control; (c) code for identifying those data points having measures of difference as calculated in (h) that are greater than a threshold value; and (d) code fhr applying an algorithm to the data points identified in (c) to thereby create a model for classifying hepatocytes according to whether they exhibit steatosis based on a second subset of the set of phenotypic features.</p><p>
- 29. The computer program product of claim 28, wherein the phenotypic features are obtained automatically by image analysis.</p><p>
- 30. The computer program product of claim 28, wherein the measure of difference calculated in (b) is a Euclidean distance or a Manhattan distance.</p><p>
- 3 1. The computer program product of claim 28, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytes.</p><p>
- 32 The computer program product of claim 28, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>
- 33. The computer program product of claim 28, wherein the set of phenotypic features is derived from at least one marker fbr a neutral lipid and at least one marker for a phospholipid.</p><p>
- 34. The computer program product of claim 28, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP.</p><p>
- 35. The computer program product of claim 28, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree.</p><p>
- 36. The computer program product of claim 28, wherein code for applying an algorithm to the data points to thereby create a model comprises code for applying a random forest algorithm to the data points.</p><p>I I * I I I I * I I I I I :.. .:. *
- 37. A method of producing a model for classifying stimuli based on whether they induce steatosis, the method comprising: receiving images of cells which have been exposed to stimuli and treated with one or more markers for cellular components in the cells; automatically extracting two or more phenotypic features from the one or more markers in the images; providing a training set comprising data points, each data point comprising (i) the two or more phenotypic features and (ii) an indication of whether the applied stimulus induces steatosis in the cells from which the phenotypic features were obtained; and generating a model from the training set, the model classifying stimuli according to whether they induce steatosis.</p><p>
- 38. The method of claim 37, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear component, a marker for general protein content within a cell, or a marker for a lipid.</p><p>
- 39. The method of claim 37, wherein the markers from which the phenotypic features are extracted comprise at least one marker for a neutral lipid and at least one marker thr a phospholipid.</p><p>
- 40. The method of claim 37, wherein the markers from which the phenotypic features are extracted comprise at least one marker for BSEP and at least one marker for MRP2.</p><p>
- 41. The method of claim 37, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>
- 42. The method of claim 37, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>
- 43. The method of claim 37, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>
- 44. The method of claim 37, wherein the model for classifying stimuli comprises a decision tree.</p><p> : * : . . * * S. S *5I *l*
- 45. The method of claim 37, wherein generating the model comprises applying a random forest algorithm to the training set.</p><p>
- 46. The method of claim 37, wherein providing the training set comprises selecting data points for stimuli having a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>
- 47. The method of claim 46, wherein selecting data points is performed for stimuli indicated to exhibit steatosis.</p><p>
- 48. The method of claim 46, wherein selecting data points is performed for stimuli indicated to exhibit steatosis and for stimuli not indicated to exhibit steatosis.</p><p>
- 49. A computer implemented method of classifying a stimulus according to whether U induces steatosis, the method comprising: receiving at least one image of cells which have been exposed to the stimulus and treated with one or more markers for cellular components in the cells; automatically extracting two or more phenotypic features from the one or more markers in the image; applying the two or more phenotypic features to a model for classifying stimuli according to whether they induce steatosis; and receiving a steatosis classification for the stimulus as an output from the model.</p><p>
- 50. The method of claim 49, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear component, a marker for general protein content within a cell, or a marker for a lipid.</p><p>
- 51. The method of claim 49, wherein the markers from which the phenotypic features are extracted comprise at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>
- 52. The method of claim 49, wherein the markers from which the phenotypic features are extracted comprise at least one marker for BSEP and at least one marker for MRP2.</p><p> 0 * * . * * * * . I.. *** S S
- 53. The method of claim 49, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>
- 54. The method of claim 49, wherein at least one ol the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>
- 55. The method of claim 49, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>
- 56. The method of claim 49, wherein the model for classifying stimuli comprises a decision tree.</p><p>
- 57. The method of claim 49, further comprising, prior to applying the two or more phenotypic features to a model, determining that the stimulus has a level of activity sullicient to induce a change greater than a defined magnitude in at least some phenotypic fiatures.</p><p>
- 58. The method of claim 49, wherein the method is performed without determining whether the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>
- 59. A computer program product comprismg a machine readable medium on which is provided program instructions for producing a model for classifying stimuli based on whether they induce steatosis, the instructions comprising: code lhr receiving images of cells which have been exposed to stimuli and treated with one or more markers for cellular components in the cells; code for automatically extracting two or more phenotypic features from the one or more markers in the images; code for providing a training set comprising data points, each data point compnsing (i) the two or more phenotypic features and (ii) an indication of whether the applied stimulus induces steatosis in the cells from which the phenotypic features were obtained; and code for generating a model from the training set, the model classifying stimuli according to whether they induce steatosis. y *</p><p>I I I $</p><p>I I I</p><p>I.. III I
- 60. The computer program product of claim 59, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear component, a marker for general protein content within a cell, or a marker for a lipid.</p><p>
- 61. The computer program product of claim 59, wherein the markers from which the phenotypic features are extracted comprise at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>
- 62. The computer program product of claim 59, wherein the markers from which the phenotypic features are extracted comprise at least one marker for BSEP and at least one marker for MRP2.</p><p>
- 63. The computer program product of claim 59, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>
- 64. The computer program product of clwm 59, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>
- 65. The computer program product of claini 59, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>
- 66. The computer program product of claini 59, wherein the model for classifying stimuli comprises a decision tree.</p><p>
- 67. The computer program product of claim 59, wherein code for generating the model comprises code for applying a random forest algorithm to the training set.</p><p>
- 68. The computer program product of claim 59, wherein code for providing the training set comprises code for selecting data points for stimuli having a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>
- 69. The computer program product of claim 68, wherein selecting data points is performed for stimuli indicated to exhibit steatosis.</p><p>I I * . I a I * * a I I I * a * a Is.</p><p>
- 70. The computer program product of claim 68, wherein selecting data points is performed for stimuli indicated to exhibit steatosis and for stimuli not indicated to exhibit steatosis.</p><p>
- 71. A computer program product comprising a machine readable medium on which is provided program instructions for classifying a stimulus according to whether it induces steatosis, the instructions comprising: code for receiving at least one image of cells which have been exposed to the stimulus and treated with one or more markers for cellular components in the celis; code for automatically extracting two or more phenotypic features from the one or more markers in the image; code for applying the two or more phenotypic features to a model for classifying stimuli according to whether they induce steatosis; and code for receiving a steatosis classification for the stimulus as an output from the model.</p><p>
- 72. The computer program product of claim 71, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear component, a marker for general protein content within a cell, or a marker for a lipid.</p><p>
- 73. The computer program product of claim 71, wherein the markers froni which the phenotypic features are extracted comprise at least one marker for a neutral hpid and at least one marker for a phospholipid.</p><p>
- 74. The computer program product of claim 71, wherein the markers from which the phenotypic features are extracted comprise at least one marker tbr BSEP and at least one marker for MR P2.</p><p>
- 75. The computer program product of claim 71, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>
- 76. The computer program product of claim 71, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells. ,</p><p>:.. :.</p><p>
- 77. The computer program product of claim 71, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>78. The computer program product of claim 71, wherein the model for classifying stimuli comprises a decision tree.</p><p>79. The computer program product of claim 7!, further comprising code for, prior to applying the two or more phenotypic features to a model, determining that the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>80. The computer program product of claim 71, wherein the program instructions comprise code for classifying a stimulus according to whether it induces steatosis without deteniiining whether the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>81. A computer implemented method of classifying a hepatocyte or population of hepatocytcs according to whether ii exhibits steatosis substantially as hereinhefore described.</p><p>82. A computer implemented method of producing a model fbr classifying hepatocytes according to a whether they exhibit steatosis substantially as hereinbefore described.</p><p>83. A computer program product comprising a machine readable medium on which is provided program instructions for producing a model for classifying stimuli based on whether they induce steatosis steatosis substantially as hereinbefore described.</p><p>84. A computer program product comprising a machine readable medium on which is provided program instructions for classifying a stimulus according to whether it induces steatosis substantially as hereinbefore described.</p><p>Amendments to the claims have been filed as follows CLAIMS: 1. A computer implemented method of classifying a hepatocyte or population of hepatocytes according to whether it exhibits steatosis, the method comprising: (a) receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (b) using at least a first subset of the set of phenotypic features of the hepatocyte or population of hepatocytes to determine whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype; (c) if the hepatocyte or hepatocytes is determined in (b) to exhibit a phenotype that is significantly different from the negative control phenotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a model for classifying cells based on whether they exhibit steatosis; and *. 15 (d) receiving a steatosis classification for the hepatocyte or population of * : :: :* hepatocytes as an output from the model. * I.</p><p>2. The method of claim 1, further comprising obtaining the set of phenotypic features S..</p><p>of the hepatocyte or population of hepatocytes by automated image analysis of : * : ::* 20 hepatocytes exposed to a stimulus. S..</p><p>I</p><p>3. The method of claim 2, wherein the stimulus comprises exposure to a compound suspected of inducing steatosis.</p><p>4. The method of claim 1, wherein determining in (b) whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype comprises: (i) in a multi-dimensional phenotypic feature space, calculating a measure of difference between at least a first subset of the set of phenotypic features of the hepatocyte or population of hepatocytes and corresponding phenotypic features of the negative control; and (ii) determining that the measure of difference calculated in (i) is greater than a threshold value.</p><p>5. The method of claim 1, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytes.</p><p>6. The method of claim 1, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>7. The method of claim 1, wherein the set of phenotypic features is derived from at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>8. The method of claim 1, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP.</p><p>9. The method of claim 1, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree. * **</p><p>* : 10. A computer implemented method of producing a model for cIassiing ** S hepatocytes according to a whether they exhibit steatosis, the method comprising: : * : ::* 20 (a) receiving data points, each comprising (i) a set of phenotypic features of a *. hepatocyte or population of hepatocytes, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP, and (ii) an indication of whether steatosis is exhibited; (b) in a multi-dimensional phenotypic feature space, calculating a measure of difference, for each of the data points, between at least a first subset of the set of phenotypic features of the data point and corresponding phenotypic features of a negative control; (c) identifying those data points having measures of difference as calculated in (b) that are greater than a threshold value; and (d) applying an algorithm to the data points identified in (c) to thereby create a model for classifying hepatocytes according to whether they exhibit steatosis based on a second subset of the set of phenotypic features.</p><p>11. The method of claim 10, wherein the phenotypic features are obtained automatically by image analysis.</p><p>12. The method of claim 10, wherein the measure of difference calculated in (b) is a Euclidean distance or a Manhattan distance.</p><p>13. The method of claim 10, wherein the set of phenotypic features comprises at least one fcature characterizing the presence of lipid vesicles within hepatocytes.</p><p>14. The method of claim 10, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>15. The method of claim 10, wherein the set of phenotypic features is derived from at *. 15 least one marker for a neutral lipid and at least one marker for a phospholipid. * * * SS</p><p>* *. 16. The method of claim 10, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree. S. * *</p><p>: : 20 17. The method of claim 10, wherein applying an algorithm to the data points to * * thereby create a model comprises applying a random forest algorithm to the data points.</p><p>18. A computer program product comprising a machine readable medium on which is provided program instructions for classifying a hepatocyte or population of hepatocytes according to whether it exhibits steatosis, the instructions comprising: (a) code for receiving a set of phenotypic features of the hepatocyte or population of hepatocytes; (b) code for determine whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different from a negative control phenotype using at least a first subset of the set of phenotypic features of the hepatocyteor population of hepatocytes; (c) code for, if the hepatocyte or hepatocytes is determined in (b) to exhibit a phenotype that is significantly different from the negative control phenotype, providing a second subset of the set of phenotypic features from the hepatocyte or population of hepatocytes as an input to a model for classifying cells based on whether they exhibit steatosis; and (d) code for receiving a steatosis classification for the hepatocyte or population of hepatocytes as an output from the model.</p><p>19. The computer program product of claim 18, further comprising code for obtaining the set of phenotypic features of the hepatocyte or population of hepatocytes by automated image analysis of hepatocytes exposed to a stimulus.</p><p>20. The computer program product of claim 18, wherein the stimulus comprises exposure to a compound suspected of inducing steatosis.</p><p>21. The computer program product of claim 18, wherein code for determining in (b) *IS.</p><p>* ., whether the hepatocyte or hepatocytes exhibit a phenotype that is significantly different * * from a negative control phenotype comprises: (1) code for, in a multi-dimensional phenotypic feature space, calculating a measure of difference between at least a first subset of the set of phenotypic : : 20 features of the hepatocyte or population of hepatocytes and corresponding 0s phenotypic features of the negative control; and (ii) code for determining that the measure of difference calculated in (i) is greater than a threshold value.</p><p>22. The computer program product of claim 18, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytes.</p><p>23. The computer program product of claim 18, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>V</p><p>24. The computer program product of claim 18, wherein the set of phenotypic features is derived from at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>25. The computer program product of claim 18, wherein the set of phenotypic features is derived from at least one marker for MRP2 and at least one marker for BSEP.</p><p>26. The computer program product of claim 18, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree.</p><p>27. A computer program product comprising a machine readable medium on which is provided program instructions for producing a model for classifying hepatocytes according to a whether they exhibit steatosis, the instructions comprising: (a) code for receiving data points, each comprising (i) a set of phenotypic features of a hepatocyte or population of hepatocytes, wherein the set of phenotypic * *** features is derived from at least one marker for MRP2 and at least one marker for * ** BSEP, and (ii) an indication of whether steatosis is exhibited; (b) code for, in a multi-dimensional phenotypic feature space, calculating a *** measure of difference, for each of the data points, between at least a first subset of : * : 20 the set of phenotypic features of the data point and corresponding phenotypic *. features of a negative control; (c) code for identifying those data points having measures of difference as calculated in (b) that are greater than a threshold value; and (d) code for applying an algorithm to the data points identified in (c) to thereby create a model for classifying hepatocytes according to whether they exhibit steatosis based on a second subset of the set of phenotypic features.</p><p>28. The computer program product of claim 27, wherein the phenotypic features are obtained automatically by image analysis.</p><p>29. The computer program product of claim 27, wherein the measure of difference calculated in (b) is a Euclidean distance or a Manhattan distance.</p><p>30. The computer program product of claim 27, wherein the set of phenotypic features comprises at least one feature characterizing the presence of lipid vesicles within hepatocytes.</p><p>31 The computer program product of claim 27, wherein the set of phenotypic features comprises at least one feature characterizing canalicular structures at the periphery of hepatocytes.</p><p>32. The computer program product of claim 27, wherein the set of phenotypic features is derived from at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>33. The computer program product of claim 27, wherein the model for classifying cells based on whether they exhibit steatosis comprises a decision tree. S. * . * *..</p><p>* * 34. The computer program product of claim 27, wherein code for applying an S S* S algorithm to the data points to thereby create a model comprises code for applying a * random forest algorithm to the data points.</p><p>: * : ::* 20 35. A method of producing a model for classifying stimuli based on whether they induce steatosis, the method comprising: receiving images of cells which have been exposed to stimuli and treated with one or more markers for cellular components in the cells; automatically extracting two or more phenotypic features from the one or more markers in the images, wherein the markers from which the phenotypic features are extracted comprise at least one marker for BSEP and at least one marker for MRP2; providing a training set comprising data points, each data point comprising (i) the two or more phenotypic features and (ii) an indication of whether the applied stimulus induces steatosis in the cells from which the phenotypic features were obtained; and generating a model from the training set, the model classifying stimuli according to whether they induce steatosis.</p><p>36. The method of claim 35, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear component, a marker for general protein content within a cell, or a marker for a lipid.</p><p>37. The method of claim 35, wherein the markers from which the phenotypic features are extracted comprise at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>38. The method of claim 35, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>39. The method of claim 35, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>**.*. 15 40. The method of claim 35, wherein at least one of the features is extracted from *... . . . . . segmented regions of the images corresponding to granules or peripheral regions within : the cells.</p><p>SASS</p><p>* 41. The method of claim 35, wherein the model for classifying stimuli comprises a : .. 20 decision tree. *SS.</p><p>S *.</p><p>S</p><p>42. The method of claim 35, wherein generating the model comprises applying a random forest algorithm to the training set.</p><p>43. The method of claim 35, wherein providing the training set comprises selecting data points for stimuli having a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>44. The method of claim 43, wherein selecting data points is performed for stimuli indicated to exhibit steatosis.</p><p>45. The method of claim 43, wherein selecting data points is performed for stimuli indicated to exhibit steatosis and for stimuli not indicated to exhibit steatosjs.</p><p>46. A computer implemented method of classifying a stimulus according to whether it induces steatosis, the method comprising: receiving at least one image of cells which have been exposed to the stimulus and treated with one or more markers for cellular components in the cells; automatically extracting two or more phenotypic features from the one or more markers in the image, wherein the markers from which the phenotypic features are extracted comprise at least one marker for BSEP and at least one marker for MRP2; applying the two or more phenotypic features to a model for classifying stimuli according to whether they induce steatosis; and receiving a steatosis classification for the stimulus as an output from the model.</p><p> 15 47. The method of claim 46, wherein at least one of the one or more markers * : :: :* comprises a marker for a canalicular component, a marker for nuclear component, a : * marker for general protein content within a cell, or a marker for a lipid. S... S..</p><p>48. The method of claim 46, wherein the markers from which the phenotypic features : * : 20 are extracted comprise at least one marker for a neutral lipid and at least one marker for a *. phospholipid.</p><p>49. The method of claim 46, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>50. The method of claim 46, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>51. The method of claim 46, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>52. The method of claim 46, wherein the model for classifying stimuli comprises a decision tree.</p><p>53. The method of claim 46, further comprising, prior to applying the two or more phenotypic features to a model, determining that the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>54. The method of claim 46, wherein the method is performed without determining whether the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>55. A computer program product comprising a machine readable medium on which is provided program instructions for producing a model for classifying stimuli based on whether they induce steatosis, the instructions comprising: I... . . . . code for receiving images of cells which have been exposed to stimuli and treated * with one or more markers for cellular components in the cells; : code for automatically extracting two or more phenotypic features from the one or I. U more markers in the images, wherein the markers from which the phenotypic features are : *. 20 extracted comprise at least one marker for BSEP and at least one marker for MRP2; S...</p><p>* . code for providing a training set comprising data points, each data point comprising (i) the two or more phenotypic features and (ii) an indication of whether the applied stimulus induces steatosis in the cells from which the phenotypic features were obtained; and code for generating a model from the training set, the model classifying stimuli according to whether they induce steatosis.</p><p>56. The computer program product of claim 55, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear component, a marker for general protein content within a cell, or a marker for a lipid.</p><p>57. The computer program product of claim 55, wherein the markers from which the phenotypic features are extracted comprise at least one marker for a neutral lipid and at least one marker for a phospholipid.</p><p>59. The computer program product of claim 55, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>60. The computer program product of claim 55, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>61. The computer program product of claim 55, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>62. The computer program product of claim 55, wherein the model for classifying stimuli comprises a decision tree.</p><p>S * S *S..</p><p>* 63. The computer program product of claim 55, wherein code for generating the model comprises code for applying a random forest algorithm to the training set. S..</p><p>S</p><p>: * . 20 64. The computer program product of claim 55, wherein code for providing the **S.</p><p>training set comprises code for selecting data points for stimuli having a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>65. The computer program product of claim 64, wherein selecting data points is performed for stimuli indicated to exhibit steatosis.</p><p>66. The computer program product of claim 64, wherein selecting data points is performed for stimuli indicated to exhibit steatosis and for stimuli not indicated to exhibit steatosis.</p><p>67. A computer program product comprising a machine readable medium on which is provided program instructions for classifying a stimulus according to whether it induces steatosis, the instructions comprising: code for receiving at least one image of cells which have been exposed to the stimulus and treated with one or more markers for cellular components in the cells; code for automatically extracting two or more phenotypic features from the one or more markers in the image, wherein the markers from which the phenotypic features are extracted comprise at least one marker for BSEP and at least one marker for MRP2; code for applying the two or more phenotypic features to a model for classifying stimuli according to whether they induce steatosis; and code for receiving a steatosis classification for the stimulus as an output from the model.</p><p>68. The computer program product of claim 67, wherein at least one of the one or more markers comprises a marker for a canalicular component, a marker for nuclear *::: :* component, a marker for general protein content within a cell, or a marker for a lipid. * ..</p><p>69. The computer program product of claim 68, wherein the markers from which the S..</p><p>phenotypic features are extracted comprise at least one marker for a neutral lipid and at : *** 20 least one marker for a phospholipid. S... a S..</p><p>70. The computer program product of claim 67, wherein at least one of the features is extracted from segmented regions of the images corresponding to nuclei within the cells.</p><p>71. The computer program product of claim 67, wherein at least one of the features is extracted from segmented regions of the images corresponding to whole cells.</p><p>72. The computer program product of claim 67, wherein at least one of the features is extracted from segmented regions of the images corresponding to granules or peripheral regions within the cells.</p><p>73. The computer program product of claim 67, wherein the model for classifying stimuli comprises a decision tree.</p><p>74. The computer program product of claim 67, further comprising code for, prior to applying the two or more phenotypic features to a model, determining that the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>75. The computer program product of claim 67, wherein the program instructions comprise code for classifying a stimulus according to whether it induces steatosis without determining whether the stimulus has a level of activity sufficient to induce a change greater than a defined magnitude in at least some phenotypic features.</p><p>76. A computer implemented method of classifying a hepatocyte or population of hepatocytes according to whether it exhibits steatosis substantially as hereinbefore I. * * 15 described. * I.. I,.. * 4 I. S</p><p>* * 77. A computer implemented method of producing a model for classifying S hepatocytes according to a whether they exhibit steatosis substantially as hereinbefore SI.</p><p>described. * ** * I I *4I5</p><p>*:.
- 78. A computer program product comprising a machine readable medium on which is provided program instructions for producing a model for classifying stimuli based on whether they induce steatosis substantially as hereinbefore described.</p><p>79. A computer program product comprising a machine readable medium on which is provided program instructions for classifying a stimulus according to whether it induces steatosis substantially as hereinbefore described. c-iL)</p>
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/005980 WO2007103531A2 (en) | 2006-03-09 | 2007-03-07 | Cellular predictive models for toxicities |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78107906P | 2006-03-09 | 2006-03-09 | |
US78257306P | 2006-03-14 | 2006-03-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0605358D0 GB0605358D0 (en) | 2006-04-26 |
GB2435924A true GB2435924A (en) | 2007-09-12 |
Family
ID=36292920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0605358A Withdrawn GB2435924A (en) | 2006-03-09 | 2006-03-17 | Cellular predictive models for steatosis |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2435924A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050002552A1 (en) * | 2003-04-30 | 2005-01-06 | Pfizer Inc | Automated in vitro cellular imaging assays for micronuclei and other target objects |
US20050014217A1 (en) * | 2003-07-18 | 2005-01-20 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
WO2005050563A2 (en) * | 2003-11-17 | 2005-06-02 | Aureon Biosciences Corporation | Pathological tissue mapping |
-
2006
- 2006-03-17 GB GB0605358A patent/GB2435924A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050002552A1 (en) * | 2003-04-30 | 2005-01-06 | Pfizer Inc | Automated in vitro cellular imaging assays for micronuclei and other target objects |
US20050014217A1 (en) * | 2003-07-18 | 2005-01-20 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
WO2005050563A2 (en) * | 2003-11-17 | 2005-06-02 | Aureon Biosciences Corporation | Pathological tissue mapping |
Also Published As
Publication number | Publication date |
---|---|
GB0605358D0 (en) | 2006-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070250301A1 (en) | Normalizing cell assay data for models | |
US20070250270A1 (en) | Cellular predictive models for toxicities | |
US7817840B2 (en) | Predicting hepatotoxicity using cell based assays | |
Huh et al. | Automated mitosis detection of stem cell populations in phase-contrast microscopy images | |
US7817841B2 (en) | Time-lapse cell cycle analysis of unstained nuclei | |
WO2007103531A2 (en) | Cellular predictive models for toxicities | |
US7235353B2 (en) | Predicting hepatotoxicity using cell based assays | |
US20050282208A1 (en) | Cellular phenotype | |
CA3193025A1 (en) | Methods and systems for predicting neurodegenerative disease state | |
US20070206845A1 (en) | Granularity analysis in cellular phenotypes | |
US20240029247A1 (en) | Systems and methods for quantitative phenotyping of biological fibrilar structures | |
WO2007103492A2 (en) | Cellular predictive models for toxicities | |
WO2007103535A2 (en) | Cellular predictive models for toxicities | |
US20070082327A1 (en) | Cellular phenotype | |
GB2435926A (en) | Cellular predictive models for phospholipidosis | |
GB2435924A (en) | Cellular predictive models for steatosis | |
GB2435922A (en) | Cellular predictive models for cholestasis | |
US20070202519A1 (en) | Domain segmentation and analysis | |
Adiga et al. | Mapping infected cell phenotype | |
US20050014131A1 (en) | Methods and apparatus for investigating side effects | |
US10867208B2 (en) | Unbiased feature selection in high content analysis of biological image samples | |
Mohammed et al. | IDCIA: Immunocytochemistry Dataset for Cellular Image Analysis | |
Vandenberghe | 3D whole-brain quantitative histopathology: methodology and applications in mouse models of Alzheimer's disease | |
On | Computational Video Bioinformatics for Understanding the Dynamics of Living Cells | |
KR20130089463A (en) | Method and apparatus for generating gene expression profile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |